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RÉSUMÉ 
 
Le sunitinib est un inhibiteur de tyrosine kinase qui est utilisée comme agent anticancéreux. 
Bien que l'utilisation clinique du sunitinib représente une percée significative pour le 
traitement de certains cancers, ce médicament s’avère cardiotoxique chez plusieurs 
patients, une situation qui est problématique. Le sunitinib peut provoquer une hypertension, 
des arythmies, une chute de la fraction d'éjection ventriculaire gauche et une insuffisance 
cardiaque congestive qui peut être fatale. Le mécanisme responsable de la cardiotoxicité de 
sunitinib n’est pas encore bien compris. Comme plusieurs autres inhibiteurs des récepteurs 
de la tyrosine kinase, il se lie à un grand nombre de kinases et  peut affecter de nombreux 
processus cellulaires. In vivo, les mécanismes responsables de la toxicité sont complexes et 
imprévisibles et une insuffisance cardiaque est parfois observée tôt pendant le traitement. 
La séquence des évènements menant à l'apparition d’une dysfonction cardiaque pendant le 
traitement n’est pas connue. Cela pose un problème important pour le diagnostic de 
complications cardiovasculaires avant qu'elles ne deviennent symptomatiques. Une 
identification précoce de ces événements néfastes serait très bénéfique pour le suivi du 
traitement au sunitinib. La tomographie d'émission par positrons (TEP) est une méthode 
reconnue pour l’évaluation du métabolisme et de la fonctionnalité du myocarde. Selon 
notre hypothèse de travail, une insuffisance cardiaque peut survenir rapidement pendant le 
traitement au sunitinib, elle est l’expression d’altérations structurelles et métaboliques au 
niveau du myocarde; ces modifications se produisent tôt pendant le traitement. Nous avons 
effectué une étude pour évaluer la faisabilité d’utiliser l’imagerie TEP pour la détection 
précoce de la cardiotoxicité induite par le sunitinib. La première étape a été de développer 
un modèle de cardiotoxicité chez des souris. L’induction de la cardiotoxicité s’est faite par 
administration orale pour une période de quatre semaines, soit de sunitinib 80mg/Kg/jour 
ou d'eau pour les souris contrôles. Le suivi inclut la mesure de la pression sanguine, 
l’évaluation des altérations biochimiques, l’expression de certains gènes et un examen 
histologique du myocarde. Un suivi par imagerie TEP a été effectué chaque semaine avec 
du 11C-acétate et du 18F-FDG afin d'évaluer le flux sanguin myocardique (MBF), le 
métabolisme oxydatif du myocarde incluant la consommation d'oxygène (MVO2), 
l'absorption du glucose (Ki), le taux métabolique oxydatif du glucose (MMRG) ainsi que la 
fraction d'éjection ventriculaire gauche (FEVG). Les résultats que nous avons obtenus par 
histopathologie, immunocoloration et microscopie électronique montrent que notre modèle 
est capable d’induire une cardiotoxicité.  Nous avons également observé des évidences 
d'inflammation et de remodelage tissulaire à partir de l’étude de l'expression de certains 
gènes et de l’analyse de l’accumulation de collagène. Nous n’avons pas observé 
d’hypertension ni de lésions rénales. La TEP avec 18FDG a montré une diminution rapide 
de la FEVG, une indication d’une dysfonction cardiaque qui a été classée comme 
insuffisance cardiaque de grade 2 à la fin de l'étude. Cependant, aucun signe de 
modifications du métabolisme cardiaque n’a été mis en évidence par TEP/18FDG- ou 
TEP/11C-acétate. Nos résultats laissent penser que l'apparition de la dysfonction contractile 
induite par sunitinib peut se produire en l'absence d'hypertension ou de dommages 
métaboliques manifestes. De nouvelles études avec des traitements plus longs permettraient 
peut être de mieux définir le début de la cardiotoxicité métabolique. 
 
Mots-clés: Tomographie d'émission par positrons, sunitinib, cardiotoxicité, FEVG. 
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ABSTRACT 
 
Sunitinib (Sutent®) is a multitargeted, small molecule receptor tyrosine kinase inhibitor 
used as an anti-cancer drug. It has increased the overall survival rate of metastatic renal cell 
carcinoma patients as well as the survival time of patients with pancreatic neuroendocrine 
tumors. Although the clinical use of sunitinib is a significant leap forward in the therapy of 
those cancers, its induction of cardiac toxicity in a substantial fraction of patients remains a 
critical problem. Sunitinib may cause hypertension, arrhythmias, drop of the left ventricular 
ejection fraction and congestive heart failure, fatal in some cases. These side effects are a 
frequent reason for interruption of its use. The mechanism(s) underlying sunitinib 
cardiotoxicity are not fully understood. Similar to other receptor tyrosine kinase inhibitors, 
it binds to a large number of cellular kinases, thus it can affect multiple cellular processes. 
In vivo, the pattern of toxicity is complex and unpredictable, with symptomatic heart failure 
sometimes observed early during treatment. The pattern of events preceding the onset of 
symptomatic cardiac dysfunction during treatment is not established. This represents a 
significant problem for the clinical diagnosis of cardiovascular complications before they 
become symptomatic. The identification and early detection of those events would be 
highly-beneficial for the clinical management of anti-cancer therapy with sunitinib.  
 
Positron Emission Tomography (PET) is recognized for its ability to probe metabolic and 
functional aspects of myocardial function. Under the working concept that heart failure can 
occur early during sunitinib treatment, and may be sustained by early myocardial metabolic 
and structural alterations, we performed a study with the objective of assessing the use of 
PET for the early detection of sunitinib-induced cardiotoxicity. For this, we established a 
model of cardiotoxicity in C57BL/6 male mice given 80mg/Kg/day of sunitinib or water, 
orally for 4 weeks. General and cardiac toxicity were monitored by biochemical, 
microscopical (H&E, immunofluorescence and electron microscopy) as well as gene 
expression analyses and blood pressure measurements. PET scans were performed weekly 
using 11C-acetate and 18F-FDG to evaluated the myocardial blood flow (MBF), myocardial 
oxidative metabolism through the quantification of oxygen consumption (MVO2), glucose 
uptake (Ki), myocardial metabolic rate of glucose (MMRG) and the left ventricular ejection 
fractions (LVEF). 
 
We found that sunitibib was cardiotoxic as revealed by histopathology, immunostaining 
and electron microscopy. Signs of inflammation and tissue remodeling were found by gene 
expression analyses and collagen staining. No hypertension or renal damage were detected 
on the study. FDG-PET revealed an early decrease of the LVEF, indicative of cardiac 
dysfunction, which developed into grade-2 heart failure by the end of the study. However, 
no signs of alterations in cardiac metabolism were uncovered by FDG- or 11C-acetate-PET. 
Our results hint that the onset of sunitinib-induced contractile dysfunction may occur in the 
absence of hypertension or overt metabolic damage and call for further studies with longer 
treatments to clearly mark the onset of metabolic cardiotoxicity. 
 
 
Keywords: Positron emission tomography, sunitinib, cardiotoxicity, LVEF. 
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1. INTRODUCTION 
 
1.1. Sunitinib in the treatment of cancer 
Receptor tyrosine kinases (RTK) are ubiquitous molecules that play multiple important 
roles in growth factor signaling (Schlessinger, 2014). The vast majority of RTK are formed 
by extracellular ligand-binding, trans-membrane and intracellular tyrosine kinase domains 
(Schlessinger, 2014). Normally, their cellular expression and activity are tightly controlled 
to ensure proper cellular homeostasis; however, deregulation of RTK function is a common 
occurrence in many types of human cancers (Schlessinger, 2014). Deregulation of RTK 
function may occur via several mechanisms including gain-of-function mutations, 
overexpression of the RTK or their ligands, abnormal autocrine or paracrine stimulation 
and chromosomal rearrangements leading to persistent activation of their function 
(Takeuchi and Ito, 2011). Aberrant stimulation of RTK function is largely of an oncogenic 
nature since almost invariably, it promotes survival and/or proliferation of tumor cells. 
Examples of RTK frequently altered or deregulated in cancer are the vascular endothelial 
growth factor receptors (VEGFR), epidermal growth factor receptors (EGFR), hepatocyte 
growth factor receptor (MET), fibroblast growth factor receptors (FGFR) and insulin-like 
growth factor receptor (IGFR) (Takeuchi and Ito, 2011). 
 
Given their involvement in the development of malignancies, RTK have attracted a strong 
interest as targets in anti-cancer therapies and they currently account for approximately 
20% of all drug discovery effort (Eschenhagen et al., 2011). Both, monoclonal antibodies 
(eg., trastuzumab and pertuzumab) and multiple small molecule compounds that interfere 
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with RTK function have been developed and are currently either in clinical use or in trials 
(Zhang et al., 2009). Most small molecule RTK inhibitors developed so far are ATP 
competitors (type 1 inhibitors), which recognize the active form of the kinase (Zhang et al., 
2009). In contrast, type 2 inhibitors bind to the inactive conformation of the RTK, allosteric 
inhibitors bind outside the ATP-binding site and covalent inhibitors bind irreversibly to the 
active site, inactivating the kinase (Zhang et al., 2009). 
 
Sunitinib malate (N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-
3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide), commercialized as Sutent by 
Pfizer, Inc. (New York) is a multitargeted, small molecule RTK type 1 inhibitor. It targets 
vascular endothelial growth factor receptors (VEGFR1, VEGFR2, and VEGFR3), platelet-
derived growth factor receptors (PDGFRα and PDGFRβ), colony-stimulating factor 
receptor type 1 (CSF-1R), Fms-like tyrosine kinase-3 (FLT3) and stem cell factor receptor 
(KIT) (Mellor et al., 2011). 
 
In January 2006, Sutent received accelerated approval from the FDA to be used in the 
treatment of metastatic renal cell carcinoma (RCC) patients and full approval for the 
treatment of gastrointestinal stromal tumor after disease progression on or intolerance to 
imatinib mesylate (Gleevec) (Goodman et al., 2007; Rock et al., 2007). Later on 2011, 
sunitinib was approved to treat progressive well-differentiated pancreatic neuroendocrine 
tumors in patients with unresectable, locally advanced, or metastatic disease (Raymond et 
al., 2011). In Canada, it was first approved by Health Canada in 2006 for the treatment of 
gastrointestinal stromal tumors (Health Canada, 2007). 
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Sunitinib is administered orally, typically in doses of 50 mg/day following cycles of 4 
weeks-on/2 weeks-off treatment (Speed et al., 2012; http://www.sutent.com). It is used in 
the treatment of RCC, with response rates of 47% (Neuhaus et al., 2014). Before the advent 
of sunitinib, prognosis of RCC patients was poor; at time of diagnosis, 20% of patients 
presented a metastatic state with a median survival of 16 months and a 5-years survival rate 
lower than 10% (Neuhaus et al., 2014). The introduction of sunitinib has increased the 
overall survival rate in RCC patients to over two years (Motzer et al., 2009). In a recent 
study, progression-free survival time of patients with pancreatic neuroendocrine tumors 
was shown to be elevated from 5.5 to 11.4 months (Raymond et al., 2011). 
 
1.2. Cardiac damage induced by sunitinib 
The introduction of RTK inhibitors in clinical practice has been a significant leap forward 
in the therapy of cancer. However, a major drawback in the pharmacological use of RTK 
inhibitors is their side effects (Eckstein et al., 2014; Eschenhagen et al., 2011), especially 
those concerning cardiovascular safety (Eckstein et al., 2014; Force and Kolaja, 2011; 
Garcia-Alvarez et al., 2010; Mellor et al., 2011; Shah et al., 2013). Even during phase III 
clinical trials, sunitinib treatment showed side effects indicative of cardiac toxicity in a 
significant fraction of patients, specifically hypertension and fall of the left ventricular 
ejection fraction (LVEF) (Goodman et al., 2007; Motzer et al., 2007). The repercussions of 
these cardiovascular side effects are significant since in addition to be life-threatening, 
cardiac toxicity and dysfunction have a severe impact in the overall quality of life of 
affected patients, most strongly limiting their physical mobility and causing significant 
functional and emotional distress (Berg et al., 2014). In general, the quality of life of 
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patients with heart failure is poorer than that of their age-matched peers in the general 
population and that of patients suffering from other chronic diseases (Klocek and 
Czarnecka, 2013). Moreover, when present, the side effects require additional therapeutic 
management and may even lead to the discontinuation of sunitinib treatment (Hall et al., 
2013). 
 
Early after sunitinib incorporation to the clinics as a therapy for cancer, a series of studies 
confirmed cardiac toxicity as an important side effect. The retrospective study by Chu et al. 
(Chu et al., 2007) in imatinib-resistant metastatic gastrointestinal stromal tumor patients 
showed that 11% had a cardiovascular event, with 8% congestive heart failure. Within a 
group of 36 patients treated with the FDA-approved dose of sunitinib, 28% had LVEF 
drops higher than 10% and 47% of patients developed hypertension (Chu et al., 2007). An 
Italian retrospective study with patients treated for RCC showed that 9.7% developed 
grade-3 hypertension, and 18.9% suffered from some cardiac abnormality including 6.9% 
with grade-3 LVEF dysfunction and/or congestive heart failure (Di Lorenzo et al., 2009). 
Telli et al. found that 15% of patients developed symptomatic grade-3/4 heart failure (Telli 
et al., 2008), while a large study conducted by Richards et al. found an all-grade incidence 
of congestive heart failure of 4.1% among 6935 patients included in the study (Richards et 
al., 2011). A recent meta-analysis of 36 clinical trials of RTK inhibitors, 19 of which were 
conducted with sunitinib, clearly illustrates the magnitude of the problem (Qi et al., 2014). 
The most frequently reported cardiac effects of sunitinib usage are hypertension, decrease 
of the LVEF and heart failure. 
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Sunitinib can affect cardiac function indirectly; for example, clinical and sub-clinical 
hypothyroidism have been frequently observed during treatment, although the reported 
rates are very variable; from 4% to 27% (Cella et al., 2010; Faivre et al., 2007; Wolter et 
al., 2008). Sunitinib causes thyroid tissue injury, leading to thyroid tissue destruction, 
possibly by inducing capillary regression through inhibition of VEGF signaling (Kappers et 
al., 2011) or by other mechanisms that remain still unclear (Aparicio-Gallego et al., 2011). 
It is clear though that hypothyroidism correlates with cardiac risk (Biondi, 2007) as thyroid 
hormones are responsible for the regulation of multiple cardiac genes (Klein and Danzi, 
2007). Hypothyroidism may impair cardiac contractility and increase systemic vascular 
resistance (Klein and Danzi, 2007).  
 
Sunitinib constitutes the prototype "case study" for cardiac toxicity induced by RTK 
inhibitors. In spite of that, the mechanism(s) underlying its cardiotoxicity are not fully 
understood (Force and Kolaja, 2011; Hall et al., 2013). Sunitinib, as many other RTK 
inhibitors, binds to a large number of cellular kinases (Fabian et al., 2005; Karaman et al., 
2008), thus it has the ability to affect multiple cellular processes. Sunitinib seems to possess 
both on-target and off-target side effects, related to its kinase-inhibition activity (Force and 
Kolaja, 2011). On-target side effects are based on the inhibition of kinases that could be 
beneficial from the perspective of oncology/angiogenesis but have a deleterious effect in 
cardiac physiology and metabolism. Off-target toxicity is due to non-selective inhibition of 
multiple kinases (and possibly non kinases) regardless of whether or not they contribute to 
tumor progression or survival, but that negatively impacts cardiac function (Force and 
Kolaja, 2011). 
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It is thought that the left ventricular (LV) dysfunction is the main cardiac adverse effect of 
sunitinib, resulting from cardiomyocyte toxicity aggravated by hypertension (Hutson et al., 
2008). However, the evidence linking LV dysfunction with sunitinib-induced hypertension 
is still controversial (Mellor et al., 2011; Rini, 2007), although there is little room to doubt 
that hypertension, once present, would contribute to damage the heart. Hypertension results 
from a reduction of the microvessel density and vascular areas, developing an increase in 
peripheral vascular resistance (Inai et al., 2004). It has been demonstrated that the sunitinib-
induced cardiotoxicity associates with depletion of coronary microvascular pericytes 
resulting in changes in the coronary microvasculature (Chintalgattu et al., 2013). 
 
The massive energetic demand of the heart is met by the use of both fatty acids and glucose 
as the two main energy substrates (Neely et al., 1972; Stanley et al., 2005). Healthy hearts 
draw 65-70% of energy from the oxidation of long-chain fatty acids (Neely et al., 1972) but 
in certain pathological conditions such as ischemic injury, the myocardium responds by 
switching the preferential substrate to glucose (Jaswal et al., 2011), which is a less oxygen-
demanding catabolic process (Ardehali et al., 2012). This adaptive response, if sustained, 
eventually affects the myocardial functional capacity, leading to heart failure (Dyck and 
Lopaschuk, 2006). There is solid indirect evidence indicating that sunitinib may generate 
myocardial metabolic distress; structural and functional mitochondrial abnormalities have 
been observed in patients, animal models and cultured cardiomyocytes exposed to sunitinib 
(Chu et al., 2007; French et al., 2010; Kerkela et al., 2009). Correspondingly, sunitinib 
treatment reduces the ATP concentration in cardiomyocytes (Hohenegger, 2012). However, 
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to our knowledge, direct measurements of myocardial metabolic functions in patients or 
animals treated with sunitinib have not been reported. 
 
It has been proposed that the sunitinib-induced decline in LVEF is the result of 
cardiomyocyte damage and hypertrophy (Cohen et al., 2011). Recent studies point to 
sunitinib activation of the aryl hydrocarbon receptor as the mechanism underlying 
hypertrophy of cardiomyocytes (Maayah et al., 2014). An important aspect of sunitinib 
cellular toxicity is its inhibition of the AMP-activated protein kinase (AMPK), a central 
regulator of metabolic homeostasis and ATP utilization (Greineder et al., 2011; 
Schmidinger et al., 2008). AMPK can sense imbalance in the AMP/ATP ratio and upon 
activation, restore energetic balance by stimulation of catabolic pathways that enhance ATP 
generation and by shutting down processes that consume ATP (Rios et al., 2013). In 
addition to AMPK, sunitinib inhibits the ribosomal S6 kinase (RSK1) at therapeutically 
relevant concentrations (Hasinoff et al., 2008). RSK1 acts as a pro-survival factor through 
the inhibitory phosphorilation of the pro-apoptotic factor BAD (Hasinoff et al., 2008), thus 
its inhibition may explain the observed induction of apoptosis by sunitinib (Berridge et al., 
2013; Chu et al., 2007).  
 
In vivo, the pattern of toxicity induced by sunitinib seems extremely complex and 
unpredictable, with symptomatic heart failure observed as early as 22 days after the 
beginning of treatment (Witteles and Telli, 2012). So far, there is no precise information on 
the sequence and timing of events preceding the onset of symptomatic cardiac dysfunction 
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during sunitinib treatment. The identification and early detection of such events will be 
highly-beneficial for the clinical management of anti-cancer therapies with sunitinib. 
 
1.3. Positron Emission Tomography (PET) 
PET is a nuclear medical imaging modality (Divgi, 2009) whose principle consists in the 
simultaneous detection of two pairs of collinear gamma rays of 511 keV each. Those rays 
are emitted at the same time, under a relative angle of 180˚ to each other and are registered 
by opposing detectors in a ring scanner. The process of emission is called β+ decay, in 
which photons are liberated after annihilation of a positron emitted from an unstable 
nucleus rich in protons (the radionuclide) and an electron of a nearby atom (Cherry, 2001; 
Ghosh et al., 2010). The detectors define a line of response with each true event of 
coincidence, in which the annihilation occurs somewhere along the line between the 
detectors (Anagnostopoulos et al., 2013). The line response is used to build multiple and 
sequential tomographic images which are then reconstructed three-dimensionally using a 
mathematical algorithm. The images are corrected for dead time, photon attenuation, 
random coincidences subtraction as well as scattered photons generated during the period 
of PET data acquisition. Then through the spatial distribution of the positron emitting 
radionuclide, also called radiotracer, and the appropriate kinetic analysis, it is possible to 
obtain quantitative measurements of biological parameters, suitable to provide insight into 
metabolic pathways in vivo, in real time (Chacko and Divgi, 2011).  
 
PET on itself is a non-invasive technique that can be performed in a single experiment or in 
repeated studies on the same subjects (Lancelot and Zimmer, 2010). Radiotracers are 
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usually administered at nano or picomolar concentrations, in non-pharmacological doses, 
resulting in minimal or no interference with the biological process that is being studied 
(Divgi, 2009). In addition, the spatial resolution of clinical PET (4–7 mm) is better than 
other nuclear imaging techniques such as single photon emission computed tomography 
(SPECT), which has a spatial resolution of over 10 mm (Anagnostopoulos et al., 2013). 
The spatial resolution of preclinical PET using dedicated scanners reaches 1-2 mm 
(Chatziioannou, 2002).  
 
Radiotracers used in PET aim to simulate natural molecules that form part of living 
organisms without altering their biochemical properties (Finn, 1999; Peterson and Gropler, 
2010). Radiotracers can be produced in a cyclotron, a particle (protons or deuterons) 
accelerator (Lancelot and Zimmer, 2010). Radionuclides, considered as the “label” for PET 
radiotracers, can be incorporated into relevant biomolecules, sometimes by substituting the 
corresponding stable elements for their positron-emitter isotopes. For example, the stable 
12C can be substituted by 11C; in addition, the native chemical elements in a molecular 
structure can be replaced by another element, as is the case of hydrogen replacement by 18F 
in substrates of interest (van den Hoff, 2005). Some of the most commonly-used positron 
emitting radionuclides in PET scanning are: oxygen-15 (15O), nitrogen-13 (13N), carbon-11 
(11C) and fluorine-18 (18F), with half-lives of 2, 10, 20 and 110 min, respectively.  
 
1.4. The use of PET for the detection of cardiac damage 
PET imaging is extensively used in cardiology (Klocke et al., 2003), it has mostly been 
used for the assessment of myocardial function, perfusion and metabolism (Ghosh et al., 
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2010). In fact, PET has become the gold standard for noninvasive evaluation of myocardial 
perfusion and viability, thanks to its superior detection sensitivity and its spatial and 
temporal resolution in comparison to other nuclear techniques (Bengel et al., 2009; 
Gropler, 2013). General guidelines for the use of PET in clinical cardiology have been 
published by the American Society of Nuclear Cardiology (Dilsizian et al., 2009).  
 
Healthy cardiac function depends on proper delivery of O2 and oxidizable substrates to 
sustain the generation of enough quantities of ATP. Most cardiac diseases involving 
mechanical dysfunction are associated with energetic deficits frequently caused by 
disturbances in one or more metabolic steps of ATP synthesis (Carvajal and Moreno-
Sanchez, 2003). In fact, alteration in the use of metabolic substrates is a biochemical 
hallmark of cardiac failure (Tuunanen et al., 2008). The most common functional assay 
done with PET is the detection of the LVEF but very often, functional PET is combined 
with myocardial metabolic analyses to provide information on metabolism changes under 
different physiological and pathological conditions (Anagnostopoulos et al., 2013). The 
typical metabolic parameters evaluated are either myocardial glucose uptake (Ki), 
myocardial metabolic rate of glucose (MMRG), myocardial blow flow (MBF) or 
myocardial oxygen consumption (MVO2). 
 
Several radiotracers that have been used in cardiac analyses are: 2-deoxy-2-[18F]fluoro-D-
glucose (FDG), 18 F-fluorothiaheptadecanoic acid (FTHA), 18 F-16-fluoro-4-thia-palmitate 
(FTP), oxygen-15 labeled water (H215O), Rubidium-82 (82 Rb), 13N-ammonia (13 NH3), 11C-
glucose, 11C-acetate and 11C-palmitate (Bengel et al., 2009; Ghosh et al., 2010). In this 
study we utilized FDG and 11C-acetate. 
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1.4.1. FDG 
FDG is a FDA-approved glucose analogue (Bengel et al., 2009) and the most widely-used 
PET tracer, even in clinical practice (Grassi et al., 2012; Miele et al., 2008). FDG is 
transported into the myocyte, and converted into FDG-6-phosphate after phosphorylation 
by hexokinase, similar to the initial steps of glucose metabolism. Different from glucose-6-
phosphate, this first step occurs in a unidirectional reaction because in the myocardium, the 
phosphatase for the reverse conversion is not present; therefore, 18F-FDG-6-phosphate can 
not go back to 18F-FDG (Ghosh et al., 2010). Also different from glucose, FDG-6-
phosphate is not a good substrate for glycolysis or glycogen synthesis, then it becomes 
trapped in the myocytes, which provides a strong signal for imaging (Medical Advisory 
Secretariat, 2005). 
 
Using FDG it is possible to evaluate the LVEF, Ki and MMRG. Detection of LVEF is the 
method of choice to evaluate cardiac toxicity in the clinic (Hesse et al., 2008). Due to its 
close relation to cardiac contraction, it is considered a contractile parameter (Borde et al., 
2012). The decrease in LVEF has been postulated to be a direct result of cardiomyocyte 
injury (Cohen et al., 2011). LVEF values are obtained from synchronized PET acquisition 
images with the electrocardiogram-gated to the cardiac cycle to be finally calculated using 
computer algorithms.  
 
Uptake of FDG by the myocardium has been used to reflect its degree of viability (Medical 
Advisory Secretariat, 2005). During energetic stress on the heart there is an increased 
glucose uptake that precedes and triggers left ventricular hypertrophy and cardiac severe 
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dysfunction (Young et al., 1999; Zhong et al., 2013). Increased FDG uptake can be 
observed in ischemic tissues, more so in mild to moderate ischemia (Egert et al., 1997; 
Ghosh et al., 2010; Tillisch et al., 1986), and also in heart failure (Bengel et al., 2009), 
increasing hypertrophy (Handa et al., 2007) and under dobutamine administration 
(Lautamaki et al., 2009). Excessive glucose uptake by the myocardium is associated with 
contractile dysfunction (Sen et al., 2013). However, decrease uptake of glucose can be 
present in situations of very severe ischemia (Ghosh et al., 2010) and decreased cardiac 
glucose/FDG uptake is a complicating issue consistently observed in diabetic patients 
(Israel et al., 2007; vom Dahl et al., 1993; Yokoyama et al., 2000).  
 
Ki represents the net FDG influx constant (Sen et al., 2013) and its determination was the 
first application of cardiac metabolic imaging using FDG-PET (Russell III, 2009). Together 
with the levels of blood glucose (determined independently, usually by blood 
biochemistry), Ki is used to determine MMRG, which provides information on the rate of 
glucose oxidation. MMRG is increased as the initial physiologically adaptive response in 
the onset of heart failure, whereas as the disease progresses, the utilization of glucose 
declines (Ardehali et al., 2012). Reductions in MMRG have been observed in conditions of 
altered glucose transport (Carvajal and Moreno-Sanchez, 2003). FDG-PET has been 
previously used for cardiac metabolic studies in dogs (Herrero et al., 2002), rats (Charissa 
et al., 2009; Handa et. al., 2007; Murray et. al., 2006; Sen et. al., 2013) and mice (Herrero 
et al., 2004; Stegger et. al., 2009; Tantawy and Peterson, 2010; Zhong et al., 2013). 
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1.4.2. 11C-acetate 
11C-acetate evaluates residual oxidative metabolism (Gargiulo et al., 2012), it is used to 
assess myocardial oxygen consumption (MVO2) and myocardial blood flow (MBF). The 
simultaneous measurement of these parameters has been recognized as an advantage for 
this radiotracer (Klein et al., 2001), although its clinical application has been limited and its 
use remains mainly investigational (Ghosh et al., 2010). The initial tracer uptake is 
dependent on MBF (Timmer et al., 2010), which is closely linked to myocardial energy 
production (Tawakol et al., 2003). A sustained decreased in MBF has been found to cause 
chronic down regulation of contractile function (Di Carli et al., 2000). Quantification of 
MBF using 11C-acetate has been in good agreement with MBF determined using H215O in a 
cohort of patients with hypertrophic cardiomyopathy, and in healthy subjects (Timmer et 
al., 2010). Moreover, comparisons between 13N-ammonia and 11C-acetate for the 
determination of MBF and MVO2 in rats, have demonstrated good agreements (Bentourkia 
et. al., 2002). Recently, 11C-acetate has been validated to meassure MBF and MVO2 in a 
model of congestive heart failure in rats using a rest-stress protocol (Croteau et. al., 2012).  
 
Normally, acetate undergoes activation by its conversion into acetyl-CoA and from there, 
depending on the cell type, it can be involved in either anabolic (fatty acid and cell 
membrane sysnthesis) or catabolic (through the tricarboxylic acid cycle (TCA) and 
oxidative phosphorylation to CO2 and H2O and thus producing energy) pathways (Grassi et 
al., 2012). 11C-acetate is a tracer of rapid and avid uptake by the heart (Visser, 2001), where 
acetyl-CoA is quickly converted to energy (Grassi et al., 2012). The clearance of the 11C in 
the form of 11CO2 formed by the catabolism of the 11C-acetate, is used to provide a measure 
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of the MVO2, being a reflection of the activity of the TCA cycle, which is directly coupled 
to the oxidative phosphorylation (Arakawa et al., 2010; Hussain et al., 2009; Peterson and 
Gropler, 2010; Visser, 2001). MVO2 is determined by cardiac energy demand (Brown et 
al., 1989) and it is closely coupled to the main determinants of systolic function, contractile 
state and wall stress (Knaapen et al., 2007). MVO2 reductions have been reported in 
patients with impaired left ventricular function (Schwaiger and Wolpers, 1990) and during 
ischemia (Peterson and Gropler, 2010). However MVO2 has also been found to increase 
during the progression of heart failure (Ardehali et al., 2012). 
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2. HYPOTHESIS AND OBJECTIVES 
 
Based on the accumulated knowledge from previous studies, in which alterations of 
myocardial substrate metabolism precede the contractile dysfunction in several cardiac 
conditions (Doenst et. al., 2010; Evans and Clarke, 2012; Zhong et. al., 2013), and given 
that contractile dysfunction is a frequent side effect of sunitinib that can appear in the first 
weeks of treatment (van den Brom et al., 2009; Witteles and Telli, 2012), we hypothesize 
that PET would be a useful tool to determine cardiac metabolic changes early during 
sunitinib treatment, which may contribute to understand and diagnose the onset of cardiac 
toxicity. A detailed characterization of alterations in substrate metabolism in the early 
stages of sunitinib treatment may provide insights about the pattern of cardiac 
pathophysiology generated by this drug, which can have a significant predictive value in 
clinical practice, for the early diagnosis and follow up of cardiac events. 
 
The objetive of this work is to determine if PET can be use as a tool for the early detection 
of sunitinib-induced cardiotoxicity. For this, we will establish a model of sunitinib 
cardiotoxicity in male C57BL/6 mice administered with 80mg/Kg of sunitinib or water by 
oral gavage, in a treatment schedule of 5 days-on/two days-off, for 4 weeks. 11C-acetate- 
and FDG-PET will be used to detect cardiac metabolic and functional alterations during 
treatment with sunitinib. 11C-acetate will be specifically used to study the myocardial blood 
flow (MBF) and myocardial oxidative metabolism through the quantification of oxygen 
consumption (MVO2), while FDG will be utilized to determine glucose uptake (Ki), the 
myocardial metabolic rate of glucose (MMRG) and the left ventricular ejection fraction 
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(LVEF) from the cardiac-gated FDG images to evaluate myocardial contractile function. 
Several other methods (such as microscopy and gene expression analyses) will be included 
to assess the presence of general toxicity and cardiotoxicity and to reliably demonstrate the 
presence of cardiac pathophysiology. These tests will be also extremely important to 
support the findings obtained with PET. 
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3. MATERIALS AND METHODS 
 
3.1. Sunitinib preparation 
Sunitinib (99% purity) was purchased from Euroasian Chemicals Pvt. Ltd (Mumbai, India). 
To prepare the stock solution for administrations, sunitinib was disolved in sterile water 
(Baxter Corporation, ON) at a final concentration of 11.4 mg/mL, by agitation in a 
reciprocal shaker bath (VWR Scientific, ON) at 37°C for 30 min, protected from light. The 
solution was separated in aliquots, protected from light and stored at 4°C until use.  
 
3.2. Animals 
Twelve weeks-old male C57BL/6 mice were obtained from Charles River (St-Constant, 
QC), animals were maintained under a standard 12 h light/dark cycle with free access to 
food (Rodent Laboratory Chow 5001, Purina, St. Louis, MO) and water, at a constant 
temperature of 22°C and 50% humidity. Upon arrival, the animals were let to acclimatize to 
the new environment for at least one week before the beginning of the experiments. Since 
male C57BL/6 are highly aggressive towards each other, they were each housed in 
individual cages. Following the acclimation period, the mice were randomly distributed per 
group, identified by ear clipping and the individual information on the cage. A code 
number was assigned to each animal. All the animal protocols were approved by the 
Animal Research Ethics Committee, Faculty of Medicine and Health Sciences, Université 
de Sherbrooke. 
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3.3. Experimental procedures 
In addition to the evaluation of cardiotoxicity by PET, the experimental design included 
several tests to assess the presence of general toxicity and cardiotoxicity upon sunitinib 
treatment. Those were intended to reliably demonstrate the existence of cardiac 
pathophysiology from a biological point of view, and to support the interpretation of PET 
results. The tests employed covered various biochemical, molecular and histological 
parameters. An overall view of the experimental design is shown in Figure 1. 
 
3.3.1. Sunitinib dosage and administration  
Animals were given 80mg/Kg of sunitinib or water by oral gavage, at mornings, in a 
volume of 10 ml/Kg. Treatment schedule consisted in sunitinib administration for 4 weeks 
(5 days of treatment followed by 2 days off, each week), according to previous studies (Hui 
et al., 2011; Murray et al., 2003; Pili et al., 2013). Previous to administration, sunitinib and 
vehicle were incubated for 10 min at 37°C with agitation in a reciprocal shaker bath 
protected from light. After the administration, the animals were closely observed for a 
period of 1 hour. The mice were monitored daily for signs of discomfort or symptoms of 
toxicity. Several parameters were routinely recorded, such as tail and eyes appearance, 
diarrhea, blood in feces, palmar or plantar swelling and arching of the spine, indicative of  
pain
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Figure 1. Treatment and data collection schedule of the experiments. 
  
 20 
3.3.2. Body weight and food consumption 
Body weight and food consumption were used as sensitive indicators of general toxicity of 
sunitinib treatment. Weight data was also use to adjust the volume of administration at the 
beginning of each week of treatment. The body weight was recorded using a precision 
weighing balance (Mettler Navigator TM) at day 0 and then once per week, at day 1 of each 
week. Food consumption was evaluated once per week at day 0 and during treatment, at 
day 1 of each week. Because mice have nocturnal habits and they consume most of the 
food during their active night hours (Ritskes-Hoitinga, 2004), food consumption was 
measured during the night. The day of evaluation, all the food was removed from the cages 
at 7:00 pm and a fixed, pre-weighted amount of chow (usually 8-9 g) was placed in each 
individual cage. Next day at 10:00 am (15 hours later), the remaining food was carefully 
recovered, weighted, and recorded for each individual mouse. The amount of food 
consumed per mouse during the fixed period was calculated by the difference in grams 
between the initial and the final weight of food collected, and expressed as gram of food 
consumed per gram of body weight. The average of food intake was calculated for each 
group per week of the study. 
 
3.3.3. Urine biochemistry 
Urine biochemical analyses were performed as an indication of renal damage, a known side 
effect of sunitinib treatment in cancer patients (Jha et al., 2013; Takahashi et al., 2012). At 
day 0 and at day 7 of each week of treatment, the mice were picked up gently and induced 
to urinate by bladder massage. One drop of urine was collected and applied to the reaction 
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test pad of a Siemens Multistix® 10SG reagent strip, according to the manufacturer’s 
instructions. These biochemical test strips are able to detect blood in urine.  
 
3.3.4. Blood pressure 
Systolic and diastolic blood pressures were recorded at day 0 of the experiment and at day 
7th of each week of treatment, using a tail-cuff Method (Daugherty et al., 2009) and a 
CODA-6 apparatus (Kent Scientific, Torrington, CT). Briefly, the animals were 
anesthetized under atmosphere of isoflurane via an induction chamber at a concentration of 
2 % volume and 1.5 L/min oxygen flow, then the isoflurane was reduced to 1-1.5% volume 
and 1.5 L/min oxygen delivered through a nose cone, and maintained like this for the rest 
of the procedure. This concentration of isoflurane is sufficient to ensure that the mice do 
not wake up during the blood pressure test. To prevent hypothermia during the procedure, 
the animals were warmed with a heating pad (UltraHeat™ Standard Dry Heating Pad). 
Lubricant ophthalmic ointment (Refresh Lubricant Eye Ointment Lacri-Lube) was applied 
to the eyes immediately after the mice were anesthetized, to prevent cornea dryness. The 
tail was threaded through the occlusion cuff of the CODA-6 and the cuff was gently slid as 
close to the base of the tail as possible. Tail temperature was monitored with an infra-red 
thermometer by pointing it to the tail base area. Once the temperature was stabilized 
between 35-37 °C, readings of systolic and dyastolic pressures were taken using a detection 
time of 20 seconds with lecture intervals of 5 seconds. The first five consistent readings 
were recorded and averaged for each animal. 
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3.3.5. PET imaging  
PET imaging was done at day 0 of the experiment and at day 6th and 7th of each week of 
treatment. PET scans were performed using a LabPET4, (Sherbrooke avalanche photodiode 
small animal scanner)–based small animal positron emission tomography with a field of 
view (FOV) of 3.75 cm and a LabPET8 Triumph, dual modality PET/computed 
tomography scanner (Gamma Medica-IDEAS Inc., Sherbrooke, Quebec, Canada) with a 
FOV of 7.5 cm. Both scanners have demonstrated similar imaging definition and spatial 
resolution (Bergeron et al., 2009; Bergeron et al., 2014). The scanners were calibrated by 
imaging of a cylindrical phantom that approximates the size of a mouse (24.8 ml, 26-mm 
diameter × 47-mm axial length) filled with water containing a known quantity (≈15 MBq) 
of 2-deoxy-2-[18F]fluoro-D-glucose (FDG). 
 
3.3.5.1. Radiochemicals  
The radiotracers used were 11C-acetate and FDG, produced in a TR-19 cyclotron (ACSI, 
Vancouver, Canada) at the cyclotron facility of the Department of Nuclear Medicine and 
Radiobiology, Sherbrooke Molecular Imaging Center, Université de Sherbrooke, following 
the procedures described in Authier et al. (Authier et al., 2008) and Paquette et al. 
(Paquette et al., 2012). 
 
3.3.5.2. Animals preparation 
Immediately before the scans, the animals were subjected to anesthesia with isoflurane at 
2.5% vol and 1.5 L/min oxygen flow in an induction chamber. Following the induction 
phase, the isoflurane was reduced and maintained at 1-1.5% vol and 1-1.5 L/min oxygen in 
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a constant flow delivered through a nose cone. This percentage of isoflurane has a minimal 
effect on cardiac function, compared to other volatile anesthetics (Zhou et al., 2005). To 
prevent hypothermia during the procedure, the animals were warmed with a heating pad. 
Lubricant ophthalmic ointment was applied to protect the eyes from dryness. Blood glucose 
levels were measured with a Precision Xtra glucometer (Abbott, UK) following the 
manufacturer’s instructions. Briefly, a small drop of blood was obtained by puncturing the 
distal section of the tail and the blood sample was deposit it into the test strip and read.  
 
For intravenous injection of the radiotracers a 30-gauge needle was connected to an 
intradermic polyethylene nontoxic catheter (PE10, inner diameter 0.28mm, outer diameter 
0.61mm (Becton Dickinson) and filled with heparinized saline (0.53 UI Heparine sodium 
injection USP (Sandoz, Canada) per mL saline solution (sodium chloride injection USP 
0.9%, Hospira Healthcare Corporation, Montreal) to prevent blood clotting. The catheter 
was then inserted into the caudal vein. Echocardiogram (ECG) signals were registered 
throughout the procedure using subcutaneous needle electrodes (SA Instrument Inc., NY) 
inserted in the right foreleg and the left hindpaw. The respiration was measured with a 
small pneumatic pillow sensor (SA Instrument Inc., NY) placed under the mouse thorax 
while the cutaneous temperature was registered by a small thermister probe (SA Instrument 
Inc., NY). The mice were promptly transferred to the PET scanners in the supine position 
and gently restrained to the scanner bed. During the scans, the animals were maintained 
under anesthesia (isoflurane 1.5% vol and 1.5L/min oxygen) and at a controlled 
temperature of 36 °C. The mouse was positioned with the heart in the middle of the FOV, 
with the aid of a Doppler probe (0.64 cm [1/4 in.], 9 MHz; Parks Medical Electronics). 
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3.3.5.3. 11C-acetate and FDG PET imaging protocols 
The imaging protocols used to explore whether PET can detect alterations in the oxidative 
metabolism and myocardial function during a four-weeks sunitinib treatment in this murine 
model are shown in Figure 2. 11C-acetate was specifically used to study the myocardial 
blood flow (MBF) and myocardial oxidative metabolism through the quantification of 
oxygen consumption (MVO2). FDG was utilized to determine glucose uptake (Ki), the 
myocardial metabolic rate of glucose (MMRG) and the left ventricular ejection fractions 
(LVEF) from the cardiac-gated FDG images; these parameters are indicators of myocardial 
glucose utilization and myocardial function. Doses of each radiotracer were prepared in a 
work station, equipped with a Capinter dose calibrator CRC-25R (Capinter Inc., NJ). All 
the radioactive manipulations were done following the University of Sherbrooke 
radioprotection guidelines. 
 
Since 11C-acetate has a shorter half live than FDG (20.4 min and 110 min, respectively), the 
PET scans were started with a 11C-acetate dynamic data acquisition with a pre-determined 
time of 21 minutes. One minute after the start of list mode data acquisition, a dose of 50±10 
MBq of 11C-acetate in 0.05 ml of 0.9% NaCl was administered intravenously at a flow of 
0.1 ml/min using an injection pump (Lomir BioMedical Inc., Montreal). A manual saline 
flush (~0.05-0.06 ml over a period of 30 seconds) was applied immediately after the end of 
the radiotracer injection. Ten minutes after the end of the 11C-acetate dynamics, a second 
list mode data acquisition of 46 minutes was started. One minute after the start (at minute 
32), a dose of 15±5 MBq of FDG in 0.05 ml of 0.9% NaCl at a flow of 0.1 ml/min was  
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Figure 2. 11C-acetate and FDG-PET imaging protocol (0 to 77 minutes). Dyn: list-mode 
dynamic acquisition. Gat: ECG-gated dynamic acquisition mode. 
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injected intravenously using an injection pump. A manual saline flush of ~0.05-0.06 ml 
over a period of 30 seconds was again applied immediately after the end of the FDG 
injection. Once the dynamics were completed, the animals were returned to their cages for 
recovery with free access to food and water. To prevent hypothermia during the recovery 
from anesthesia a heating pad was placed under the cage, covering approximately 50% of 
the bottom of the cage area. 
 
3.3.5.4. Image reconstructions 
For the analysis of the cardiac parameters (MVO2, MBF and MMRG), 11C-acetate and 
FDG PET images were reconstructed on a 92 x 92 x 128 matrix and on a 92 x 92 x 64 
matrix for the emission list-mode data recorded from LabPET 8 and LabPET4, 
respectively, with a common voxel size of 0.5 x 0.5 x 0.59675 mm3 using the maximum-
likelihood expectation maximization (MLEM) algorithm with 15 iterations (Selivanov et 
al., 2000). For each analysis, a series of frames was independently chosen for each 
radiotracer; 29-frame sequences were taken for 11C-acetate as follow: 1 x 1 min, 12 x 10 s, 
11 x 30 s and 5 x 150 s and 32 frames for FDG, distributed as 1 x 1 min, 12 x 15 s, 9 x 30 s, 
5 x 150 s and 5 x 300 s. 
 
The last 15-minutes frame of the cardiac FDG gated PET data acquired in the list-mode 
was also reconstructed into eight electrocardiogram gates on the basis of R-R intervals 
(Croteau et al., 2003) using MLEM algorithm with 35 iterations to calculate the left 
ventricular ejection fraction. The data from the first minute of acquisition, previous to the 
radiotracers injection, was used to evaluate the residual activity from the previous injection 
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or any accidental coincidences. The mean activity estimated from this frame in a delayed 
time window was removed from all the decay-corrected subsequent frames of the emission 
sinogramas before data analysis.  
 
3.3.5.5. Quantitative image analysis, PET variables 
Images were analyzed using the "in house" Sherbrooke LabTEP image analysis software. 
For quantitative evaluation using a kinetic modeling of both radiotracers, regions of interest 
(ROI) were manually drawn in the transaxial planes over the myocardium and in the center 
of the blood pool of the left ventricle. A third ROI was drawn for the FDG in the liver, as 
previous studies have shown that the exponentially decaying part of time activity curves are 
very similar for the arterial blood and the liver, allowing the use of the liver input curve to 
estimate the later blood clearance phase. Therefore, a hybrid input curve was generated 
using left ventricle and liver input curves for the FDG as described by Tantawy and 
Peterson (Tantawy and Peterson, 2010). Such hybrid input curve is the approach 
recommend by these authors to calculate the MMRG, rather than the use of the left 
ventricle input curve alone or the arterial input function generated from manual arterial 
blood sampling, as previously reported (Tantawy and Peterson, 2010). ROI were applied to 
each time frame of the PET images, and the average radioactivity concentration was 
computed to obtain the tissue time-activity curves. All time-activity curves were corrected 
for radionuclide decay. 
 
MBF and MVO2 were quantified from blood and myocardial time–activity curves 
generated from PET images of 11C-acetate. The curves were fitted with the PetKm software 
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(PET Kinetic Modeling, University of Sherbrooke ) (Bentourkia M., Univ of Sherbrooke, 
personal communication) and analyzed using a three-compartment kinetic model to obtain 
values for K1 (ml/g/min) and K2 (ml O2/min/100 g myocardial tissue), representing MBF 
and MVO2, respectively. 
 
For the calculation of the MMRG the FDG myocardial and hybrid input curves were fitted 
with PetKm software. The Patlak graphical analysis was chosen for the kinetic modeling. 
The interval of frames 19th-30th from FDG dynamic data, corresponding to the time period 
of minutes 7th-36th was taken. The early–time data representing the exchange of radiotracer 
between blood and myocardium were not used (Herrero et al., 2004). The mean plasma 
glucose (Cglu) levels (in mg/dl) taken before each PET imaging sesion were used for the 
calculations, and a value of 1.0 was assumed for the Lumped constant (LC) of the 
myocardium. The Ki obtained (FDG uptake constant) was then used to calculate MMRG 
through the equation: MMRG (µmol/g/min) = Ki Cglu/LC (Zhong et al., 2013). 
 
To calculate the LVEF the pixel size of the images was transformed to approximate the 
mouse heart size to human dimensions, using the XMedCon program 
(http://xmedcon.sourceforge.net/). Reorientation and cardiac data analysis were performed 
with the Corridor4DM software from Segami Oasis (Columbia, MD), as previously 
described (Croteau et al., 2003). 
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3.3.6. Animal tissue collection 
Three days after the last scan, animals were weighted and euthanized by treatment with 
isoflurane (Abbott Laboratories, ON) via an anesthesia chamber at a concentration of 5 % 
volume and 1.5 L/min oxygen flow) followed by cervical dislocation. The hearts were 
collected, rinsed with 0.9% saline solution, weighted in an analytical balance (Toledo XS, 
Mettler Toledo) and immediately dissected longitudinally and placed in the appropriate 
buffers depending on the future application.  
 
3.3.7. Histological analysis and immunofluorescent microscopy 
One half of the hearts was fixed in buffered formalin (10% formaldehyde, 33mM 
NaH2PO4, 46 mM Na2HPO4) for 24 h at room temperature, transferred to 70% ethanol and 
embedded in paraffin blocks at the pathology service of the Centre hospitalier universitaire 
de Sherbrooke (CHUS). In addition, parts of several samples were fixed in 3.5% 
paraformaldehyde and frozen-embedded in OCT (TissueTek/VWR) for immunofluorescent 
microscopy. Sections 5 µm thick were mounted on slides and either stained with 
hematoxylin & eosin (H&E) by the pathology services of the CHUS or used for detection 
of myocardial interstitial fibrosis, by staining with Masson's trichrome for collagen, 
performed at Wax-it Inc. Histology Services, Vancouver, Canada. Histological images 
were obtained using a Nanozoomer 2.0 slide scanner (Hamamatsu Photonics K. K., Japan) 
and visualized and processed with the NDP Viewer software (Hamamatsu Photonics K. K., 
Japan). Pathological damage to the hearts was evaluated by Dr. Marie Odile Benoit-
Biancamano, Department of Pathology and Microbiology, (Univ. of Montreal).  
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Frozen, 5 µm thick sections were generated using a Cryostat (Leica 3050) and used for 
immunofluorescence staining, performed as described (Guttman et al., 2006). Briefly, 
thawed sections were treated for 5 minutes in 0.2% Triton X-100 in phosphate-buffered 
saline (PBS); this was followed by three ten-minute washes with PBS. The tissues were 
blocked for 20 minutes with 5% normal goat serum/0.5% bovine serum albumin in PBS 
(GB-PBS) and then incubated with a rabbit anti-mouse myeloperoxidase-1 (MPO-1) 
(1:200, Ab-1, NeoMarkers RB 373-AD) overnight at 4°C in GB-PBS containing 0.1% 
Tween 20. The next day, the slides were washed three times for 10 minutes in 0.5% 
BSA/0.1% Tween 20 in PBS and incubated with a fluorescent goat anti-rabbit antibody 
conjugated to Alexa-488, 1:1000 dilution (Molecular Probes, CA) for 2 hours at room 
temperature. The slides were washed as before and coverslips were mounted using 
ProLongGold with 4’,6-diamidino-2-phenylindole (DAPI) (Molecular Probes), to stain the 
cell nuclei. Fluorescence was visualized using an Olympus IX81 microscope.  
 
3.3.8. Transmission electron microscope  
Fragments of the left ventricular myocardium from the heart apex were fixed in 2.5% 
glutaraldehyde in 0.1M sodium cacodylate buffer for 12 hours. After two rinses in 0.1M 
cacodylate buffer (pH 7.3) for 5 minutes, specimens were post-fixed for 90 min with 1% 
osmium tetroxide in cacodylate buffer. Tissues were rinsed twice in cacodylate buffer and 
dehydrated in increasing ethanol concentrations (70, 85, 90, and 3 x 100%) followed by 
immersion in propylene oxide three times for 5 minutes. Infiltration was conducted in a 1:1 
mixture of propylene oxide and epoxy resin (Epon 812) for 1 hour, followed by 2 x 1-hour 
and one overnight infiltration steps in 100% resin. Samples were placed into uniquely 
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labeled molds in 100% resin and polymerized in a 65°C oven for 48 h. Longitudinally 
oriented sections of tissue between 70-80 nm thick were cut from the blocks using a Leica 
ultramicrotome, contrasted with 2% uranyl acetate and 3% lead citrate. The grids were 
examined at 80 keV in a Hitachi H-7500 transmission electron microscope equipped with a 
16-megapixel AMT TR160 digital camera controlled by an Advanced Microscopy 
Techniques software. All reagents were purchased from Electron Microscopy Sciences 
(Cedarlane, ON). 
 
3.3.9. Gene expression analyses 
Gene expression analyses were performed by quantitative PCR (qPCR) on reverse-
transcribed products (cDNA) prepared from total RNA isolated from the heart's ventricular 
apex of mice randomly selected from each group. Sections of approximately 10 mg were 
excised from the left ventricle (LV) immediately after euthanizing the animals and placed 
in RNALater (Qiagen) to preserve RNA integrity. The samples were incubated overnight at 
4°C and transferred next day to -80°C until use. Total RNA was purified using the 
RNAEasy kit (Qiagen) according to the manufacturer's instructions. Briefly, the tissues 
were separately homogenized in Safe-lock 2 ml tubes (Eppendorf) containing 350 µl of 
RLT buffer with one sterile 2-mm diameter tungsten bead, using a Mixer Mill MM400 
(Retsch, Germany) at a shaking frequency of 25/second, for 4 minutes. The homogenates 
were then centrifuged at 15000 x g for 5 minutes and the supernatant was mixed with 350 
µl of 70% ethanol and loaded into the kit's columns. The columns were spun in a microfuge 
at 10000 x g for 1 minute, the flow-through was discarded and the column was washed 
with 700 µl of RWI buffer, followed by 2 washes with 500 µl of RPE buffer, by 
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centrifugation as described above. The RNA was eluted from the columns by addition of 30 
µl of RNAse-free water and centrifugation for 1 minute at 10000 x g. RNA concentrations 
were determined by optical density measurement at 260 nm using a Nanodrop 
spectrophotometer (Thermo Scientific).  
 
The cDNAs were prepared by reverse transcription of total RNA using the Quantitech 
reverse transcription kit from Qiagen, following the manufacturer's instructions. Briefly, 
500 ng of total RNA were cleaned of contaminating genomic DNA by treatment with 2 µl 
of gDNA-wipe out solution for 2 minutes at 42°C. The cDNAs were synthesized by 
addition of a mix containing the random primers, buffer and reverse-transcriptase (RT) 
enzyme followed by incubation for 30 minutes at 42°C. At the end of the cDNA synthesis 
step, the RT was inactivated by treatment for 3 minutes at 95°C and the 20 µl reactions 
were taken to a final volume of 100 µl with RNAse-free water. 
 
The qPCR reactions were done in 96-well plates (Axygen) using the iQ™ SYBR® Green 
Supermix from Biorad and an Eppendorff Real Plex-2 qPCR machine, in a final volume of 
10 µl per reaction. The reaction mixes consisted in 1 µl of cDNA, 1 µl of the gene-specific 
mix of forward and reverse primers (2 µM each), 3 µl of water and 5 µl of the 2 x qPCR 
mix. PCR conditions were: 10 minutes at 95°C to activate the enzyme followed by 40 
cycles of: 95 °C denaturing for 30 seconds, 60°C annealing for 30 seconds and 72 °C 
extension for 30 seconds. Fluorescence readings were taken during the extension part of the 
cycles. At the end of each qPCR run, a melting curve analysis of the qPCR products was 
carried out to monitor the specificity of the amplifications. Relative transcript levels were 
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calculated using the delta Cq method corrected for primer efficiencies (Pfaffl, 2001) and 
expressed as the relative expression of the sunitinib-treated group with respect to the 
control (water-treated) group. The list of genes analyzed and the sequences of the primers 
for each gene are shown in Table 1. 
 
3.3.10. Statistical analyses  
Data processing and statistical analyses were done with GraphPad Prism 6 (GraphPad 
Software, Inc., San Diego, CA). All values are expressed as group means ± standard error 
of the mean. Statistical comparisons were performed using Student's t-test.
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Table 1. The genes analyzed in this study and the qPCR primers. Relevant functions are given for each gene product. 
Gene Acc. No. Product Primers Function 
Inflammation    
Tnf NM_013693.3 Tumor necrosis factor alpha CCACCACGCTCTTCTGTCTAC 
AGGGTCTGGGCCATAGAACT 
Cytokine, inflammation 
Nos2 NM_010927.3 Nitric oxide synthase 2, inducible  CGCTTTGCCACGGACGAGA 
AGGAAGGCAGCGGGCACAT 
Inflammation 
Il6 NM_031168.1 Interleukin 6 GAGGATACCACTCCCAACAGACC 
AAGTGCATCATCGTTGTTCATACA 
Cytokine, inflammation 
Il1b NM_008361.3 Interleukin 1 beta ACGGACCCCAAAAGATGAAG 
TTCTCCACAGCCACAATGAG 
Cytokine, inflammation 
Il18 NM_008360.1 Interleukin 18 GCCTCAAACCTTCCAAATCAC 
GTTGTCTGATTCCAGGTCTCC 
Cytokine, inflammation 
Cxcl1 NM_008176.3 Chemokine (C-X-C motif) ligand 1 (KC) ACCCAAACCGAAGTCATAGC 
TCTCCGTTACTTGGGGACAC 
Chemokine, inflammation 
Hypertrophy/Remodeling   
Col1a1 NM_007742.3 Collagen, type I, alpha 1  CTCCCAGAACATCACCTATCA 
ACTGTCTTGCCCCAAGTTCCG 
Remodeling  
Cyp1a1 NM_009992.4 Cytochrome P450, family 1, subfamily a, 
polypeptide 1  
CTGGATGCCTTCAAGGACTTG 
TGTCCTGACAATGCTCAATGAG 
Marker of hypertrophy  
Areg NM_009704.3 Amphiregulin ATCTTTGTCTCTGCCATCATCC 
GTCCCGTTTTCTTGTCGAAGC 
Remodeling 
Tgfb1 NM_011577.1 Transforming growth factor, beta 1 TGACGTCACTGGAGTTGTACGG 
GGTTCATGTCATGGATGGTGC 
Inflammation/Remodeling 
Fgf21 NM_020013.4 Fibroblast growth factor 21 AATCCTGGGTGTCAAAGCCTC 
ACTGGTACACATTGTAACCGTC 
Cardiac protection 
Mitochondrial function    
Ucp2 NM_011671.4 Uncoupling protein 2 (mitochondrial, proton carrier) ACAGCCTTCTGCACTCCTG 
GGCTGGGAGACGAAACACT 
Mitochondrial function 
Ucp3 NM_009464.3 Uncoupling protein 3 (mitochondrial, proton carrier) GGATGCCTACAGAACCATCG 
TTGTGATGTTGGGCCAAGT 
Mitochondrial function 
Cox4i1 NM_009941.2 Cytochrome c oxidase subunit IV isoform 1 TCACTGCGCTCGTTCTGAT 
CGATCGAAAGTATGAGGGATG 
Mitochondrial respiration 
Cox5b NM_009942.2 Cytochrome c oxidase subunit Vb GTGGTGTCCCCACTGATGA 
TGAAGCTGCCTTTGGAGGTA 
Mitochondrial respiration 
Uqcrc1 NM_025407.2 Ubiquinol-cytochrome c reductase core protein 1 CTCAACAGACATTACAAAGCCC 
ACGGCATCTTCTTCATACACTC 
Mitochondrial respiration 
    
 35 
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Energy metabolism    
Slc2a4 
 
NM_009204.2 Solute carrier family 2 (facilitated glucose 
transporter), member 4 (Glut4) 
GTGACTGGAACACTGGTCCTA 
CCAGCCACGTTGCATTGTAG 
Glucose transporter 
CD36 NM_001159558.1 CD36 antigen  TTGTACCTATACTGTGGCTAAATGAG 
CTTGTGTTTTGAACATTTCTGCTT 
Fatty acid uptake 
Pdk4 NM_013743.2 Pyruvate dehydrogenase kinase, isoenzyme 4 GCCAATTTCTCGTCTCTACGC 
TGACTTGTTAAAGACTGGGAGC 
Metabolic regulator 
Slc27a1 NM_011977.3 Solute carrier family 27 (fatty acid transporter), 
member 1 
GGTTGACGGTGGTACTGCGC 
GTAGCGGCAGATTTCACCTATG 
Fatty acid uptake 
Pgc1a NM_008904.2 Peroxisome proliferative activated receptor, 
gamma, coactivator 1 alpha 
CCCTGCCATTGTTAAGACC 
TGCTGCTGTTCCTGTTTTC 
Transcriptional control 
Ppara NM_011144.6 Peroxisome proliferator activated receptor alpha CGGGAACAAGACGTTGTCAT 
CAGATAAGGGACTTTCCAGGTC 
Transcriptional control 
Ppard NM_011145.3 Peroxisome proliferator activator receptor delta AGAACACACGCTTCCTTCCA 
CCGACATTCCATGTTGAGG 
Transcriptional control 
Cpt1b NM_009948.2 Carnitine palmitoyltransferase 1b, muscle CATCCCAGGCAAAGAGACA  
AAGCGACCTTTGTGGTAGACA 
Lipid transport 
Acadm NM_007382.5 Acyl-Coenzyme A dehydrogenase, medium chain TGTCGAACACAACACTCGAAA 
CTGCTGTTCCGTCAACTCAA 
Lipid oxidation 
Housekeeping gene    
Rplp0 
 
NM_007475.5 Ribosomal protein, large, P0 (36B4) TCTGGAGGGTGTCCGCAAC 
CTTGACCTTTTCAGTAAGTGG 
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4. RESULTS 
 
The objective of this work was to evaluate the feasibility of 11C -acetate- and FDG-PET 
imaging for the early detection of cardiotoxicity induced by sunitinib treatment. To address 
this, we treated male C57BL/6 mice with sunutinib at a dose of 80mg/Kg/day following a 
schedule of administration of 5 days per week, for 4 weeks. The selection of male mice was 
based on previous studies in which males showed higher susceptibility to hypertrophy and 
heart failure than females. Females can develop a relative protection from the occurrence of 
cardiovascular illnesses, a phenomenon that has been found not only in animals but also in 
humans (Fliegner et al., 2010; Gurgen et al., 2011; Sari et al., 2011). 
 
Sunitinib dosing in cancer patients is typically 50mg/day, administered in 6-week treatment 
cycles of 4 weeks on/2 weeks off, as recommended by demonstrated clinical efficacy for 
advanced solid tumors (Faivre et al., 2006). We employed a dose of 80 mg/Kg/day based 
on several considerations: (i) the half-life of sunitinib in normal human volunteers has 
proven to be approximately 25-fold higher than that in mice (Chintalgattu et al., 2013; Hipp 
et al., 2008) therefore, higher doses are required for mice in order to obtain similar drug 
exposures as those achieved in humans; (ii) 80 mg/Kg/day induce a substantial and optimal 
antitumor effect in murine models (Ebos et al., 2007/; Hui et al., 2011); and (iii) high doses 
of sunitinib have been used in multiple preclinical studies in mice, either in single-dose 
administrations of 80, 120, and 160 mg/Kg (Haznedar et al., 2009; Lim et al., 2010; Welti 
et al., 2012), in repeat-dose administrations of 80 mg/Kg (Pili et al., 2013) and 120 
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mg/Kg/day for 7days (Welti et al., 2012) and also 80 mg/Kg/day for 21days (Murray et al., 
2003) and up to 4 and 5 weeks in other models (Haznedar et al., 2009). 
 
We decided to perform a 4-weeks treatment period to resemble a typical cycle of clinical 
sunitinib administration schedule, with the difference that instead of 7 days per week, the 
administration was adjusted to 5 days per week, as done in previous studies (Hui et al., 
2011; Murray et al., 2003; Pili et al., 2013). For this decision, we also took into account the 
clinical evidence of the occurrence of cardiac adverse effects during the first 4-weeks cycle 
of treatment (Chu et al., 2007; de Boer et al., 2010; Khakoo et al., 2008; Mellor et al., 2011; 
Steingart et al., 2012). 
 
4.1. Biological evaluation of general toxicity induced by sunitinib 
Based on the reported incidence of several adverse effects during sunitinib administration 
in humans, the treated animals were observed daily to detect signs of general toxicity. We 
monitored for gastrointestinal problems such as diarrhea or bloody stools, lesions of the 
skin (desquamation, blisters and callus formation in areas subjected to pressure, such as the 
paws and foot pads) as well as hair depigmentation (Aparicio-Gallego et al., 2011; Neuhaus 
et al., 2014; Schwandt et al., 2009). Other events such as anorexia, weight loss and 
hematuria, also reported in the literature (Eisen et al., 2012; Quintyne et al., 2013; 
Schwandt et al., 2009), were evaluated once per week by food consumption and body 
weight measurements, while the presence of blood in urine was determined by a 
biochemical test. 
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During the daily and individual observation of the animals, a change in the color of the 
stools was evident in the treated group from the beginning of the study. The feces became 
yellowish with respect to the controls, but no diarrhea, bloody stools or lesions of the skin 
were observed in any of the two groups throughout the experiment. The treated animals 
show signs of inactivity that started the second week of treatment, which progressively 
increased during the course of the study. A slight hair depigmentation in the group under 
sunitinib treatment was noted by the 4th week. Urine biochemical analyses performed for 
each individual mouse didn’t show any indication of blood in the urine, suggesting that the 
administration schedule and dose of sunitinib used did not induce significant renal damage. 
 
The analysis of body weight (Figure 3) revealed that the control group consistently gained 
weight during the study, from an average of 27 g at week 0 to 29.8 g at the end of the study. 
However, the treated group failed to show any increase in weight. The differences between 
the two groups became statistically significant at the 2nd week of treatment and by the 3rd 
and 4th week were highly significant. In addition, the amount of food consumed by each 
animal in a 15-hour time period, decreased in the group treated with sunitinib (Figure 4) 
starting the first week of treatment and was most remarkable after a sudden and statistically 
significant drop observed at the 3rd week. These results indicate that sunitinib 
administration at 80mg/Kg causes anorexia and weight faltering in C57 BL6 adult male 
mice. 
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Figure 3. Body weight of C57BL6 male mice at 0 (pre-treatment), 1, 2, 3 and 4 weeks of 
treatment with sunitinib 80mg/Kg. The graph shows the means and standard errors. The 
asterisks denote statistical significant differences between the sunitinib-treated and control 
groups as determined by Student’s t-test, (*) p < 0.05) and (**) p < 0.01).   
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Figure 4. Food consumption of C57BL6 male mice at 0 (pre-treatment), 1, 2, 3 and 4 
weeks of oral administration of sunitinib 80 mg/Kg. Food consumption (Food (g)/ BW(g)) 
is expressed as the ratio between food intake in a 15-hours period vs the body weight (BW) 
of the animal. The graph shows the means and standard errors. The asterisks denote 
statistical significant differences between the sunitinib-treated and control groups as 
determined by Student’s t-test, (*) p < 0.05). 
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4.2. Biological evaluation of cardiac toxicity induced by sunitinib 
Significant cardiovascular side effects have been often reported as a consequence of the 
mechanisms of action of many anti-cancer agents (Eschenhagen et al., 2011), and sunitinib 
is not the exception. Cardiac adverse effects of sunitinib treatment vary in severity from 
asymptomatic prolongation of the QTc (the heart rate-corrected time between the start of 
the Q wave and the end of the T wave in the heart's electrical cycle) (Dasanu et al., 2012) 
and hypertension to myocardial infarction and sudden death (Schmidinger et al., 2008).  
 
Hypertension is considered a mechanism by which RTK inhibitors therapy can cause left 
ventricular systolic dysfunction, heart failure, ischemia and infarction (Dasanu et al., 2012; 
Hutson et al., 2008; Shah et al., 2013). Therefore, detection of hypertension is an indicator 
for intervention against cardiac toxicity during RTK inhibitors treatment. Because RTK 
inhibitors can cause dramatic and somewhat unpredictable increases in blood pressure early 
in treatment, the National Cancer Institute clinical trial protocols recommend monitoring 
blood pressure weekly during the first cycle of RTK inhibitor therapy and then at least 
every 2 to 3 weeks for the duration of treatment (Steingart et al., 2012). It has been reported 
that sunitinib can induce significant increases in systolic and diastolic blood pressures, even 
within the first cycle (4 weeks) of treatment (Chu et al., 2007; Mellor et al., 2011; Shah et 
al., 2013). Given this precedent, we monitored blood pressure during the experiment. The 
analysis of systolic and diastolic blood pressures recorded before the beginning of the 
experiment, and at day 7th of each week of treatment using a tail-cuff method, did not differ 
between the 2 groups (Figure 5). 
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Figure 5. Systolic (A) and diastolic (B) blood pressure of C57BL6 male mice at 0 (pre-
treatment), 1, 2, 3 and 4 weeks of treatment with sunitinib 80mg/Kg. The graphs show the 
means and standard errors. SBP: Systolic blood pressure; DBP: Diastolic blood pressure. 
 
  
A 
B 
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Histological staining of 5 µm-thick heart sections with hematoxylin and eosin (H&E) was 
used to investigate the cardiac tissues of both groups, with the objective of documenting the 
occurrence of myocardial histopathological changes as a consequence of sunitinib 
treatment. The analysis of H&E-stained tissues under a light microscope showed only 
moderate pathology in some of the sunitinib-treated animals (Figure 6). Mild fibroplasia 
accompanied by hemosiderophages, consistent with chronic microhemorrhage, was 
observed, as well as abundant myofiber vacuolation and signs of early muscle degeneration 
presented by cloudy swelling possibly indicating intracellular edema. 
 
The histopathological findings showing tissue damage suggested the possibility of an 
ongoing inflammatory process. Inflammation can be triggered in response to a wide range 
of homeostatic insults, which include tissue injury (Chovatiya and Medzhitov, 2014). 
Based on this, we evaluated the expression of a battery of genes known to be involved in 
the inflammatory response in the heart under various conditions of myocardial homeostatic 
stress (Aoyagi and Matsui, 2011; Hedayat et al., 2010) (Table 1). The analysis of relative 
mRNA levels for a group of inflammatory genes in the left ventricle of sunitinib-treated 
mice, by qPCR (Figure 7), showed statistically significant upregulation of the genes coding 
for the pro-inflammatory factors TNFα (tumor necrosis factor), NOS2 (inducible nitric 
oxide synthase), IL1β (interleukin 1 beta) and CXCL1 (chemokine X-ligand 1, also known 
as KC in mice). However, a surprisingly different response was observed for the Il6 
(interleukin 6) gene, which was significantly downregulated in animals under sunitinib 
treatment. In addition, no significant change was detected in the transcript levels of the Il18  
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   Figure 6. H&E staining of cardiac tissue from representative C57BL/6 male mice orally 
   administered with vehicle (C) or sunitinib 80 mg/Kg for 4 weeks (S1 and S2). Arrows in 
   S1 indicate a zone of fibroplasia and the presence of hemosiderophages. Vacuolation and  
   intracellular edema are present in S2 as white areas in the myocardium. Scale bars are 
   250 µm (left panel) and 50 µm (right panel).  
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Figure 7. Relative transcript levels of inflammation-related genes in the left ventricle of 
C57BL/6 male mice after 4 weeks of treatment with water (control) or sunitinib 80mg/Kg. 
The data was generated by qPCR; the graph shows the means and standard errors. The 
genes evaluated were tumor necrosis factor alpha (Tnf), inducible nitric oxide synthase 
(Nos2), chemokine (C-X-C motif) ligand 1 (Cxcl1), interleukin 1 beta (Il1b), interleukin 6 
(Il6) and interleukin 18 (Il18). The asterisks denote statistical significant differences 
between the sunitinib-treated and control groups as determined by Student’s t-test, (*) p < 
0.05); (**) p < 0.01); (***) p < 0.001.   
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(interleukin 18) gene (Figure 7). The local increase in the transcript levels of this group of 
pro-inflammatory genes strongly suggests the presence of an underlying inflammatory 
process in the left ventricle of sunitinib-administered animals. 
 
CXCL1 is a chemokine that is a potent chemoattractant for neutrophils; it promotes their 
extravasation and infiltration in tissues. Neutrophils are the first inmmune cells that 
accumulate in damaged tissues (Amanzada et al., 2014), and under certain conditions, they 
can also actively contribute to the onset and perpetuation of injury (Seely et al., 2003). In 
addition neutrophil infiltration of the myocardium has been previously observed after tissue 
damage for example, in models of ischemia reperfusion injury (Ao et al., 2009). The 
increase in the relative expression of the Cxcl1 gene suggested the possibility of neutrophil 
recruitment to the myocardium of the animals treated with sunitinib. In fact, 
immunofluorescent microscopy of heart tissue sections (Figure 8), using an antibody 
against myeloperoxidase-1 (MPO-1, a marker of neutrophils) revealed a clear increase on 
the number of neutrophils in the hearts of sunitinib- treated animals with respect to the 
controls. This finding supports the idea that an active injury/inflammatory process is 
occurring in the myocardium of the sunitinib-treated mice.  
 
Myocardial hypertrophy and fibrosis have been reported to occur as a consequence of 
sunitinib administration (Chintalgattu et al., 2013; Chu et al., 2007; Kerkela et al., 2009; 
Maayah et al., 2014). While the onset of hypertrophy is the result of adaptive changes in 
the myocardium  as  a  compensatory response to stress (Frey et al., 2004), fibrosis  results  
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Figure 8. Neutrophil staining of heart sections of sunitinib-treated with 80mg/Kg and control C57BL6 male mice. Frozen sections (5 
µm) were immunostained with an anti-myeloperoxidase 1 (MPO-1) antibody. Neutrophils are stained green and cell nuclei blue 
(DAPI), panel A: untreated controls; panel B: sunitinib-treated. Scale bar is 50 µm. 
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from excessive accumulation of extracellular matrix components (mostly collagen) 
typically triggered by tissue injury and remodeling (Fan et al., 2012). Both, hypertrophy 
and fibrosis are associated to myocardial dysfunction and disease (Fan et al., 2012; Frey et 
al., 2004). An analysis of the heart weights, individually normalized against the total body 
weight, showed no differences between the sunitinib- and the vehicle-treated animals 
(Figure 9), demonstrating the absence of overt myocardial mass increase. The expression of 
Cyp1a1, a gene overexpressed in sunitinib-induced hypertrophy (Maayah et al., 2014), was 
moderately upregulated almost reaching statistically significance (Figure 10). In contrast, 
the expression of Fgf21, a member of the fibroblast growth factors family produced by 
cardiomyocytes, which protects against cardiac hypertrophy (Planavila et al., 2013), was 
slightly (but non-significantly) decreased. Taken together, these results may be interpreted 
as an indication of an early-stage hypertrophy process.  
 
Masson's trichrome staining of cardiac sections (Figure 11) revealed a mild but clear 
interstitial accumulation of collagen fibers in the myocardium, indicative of emerging 
fibrosis as a result of the sunitinib treatment. In keeping with this, the expression of the 
collagen type I alpha 1 gene (Col1a1) was upregulated (Figure 10). The amphiregulin gene 
(Areg), an epidermal growth factor receptor ligand mitogenic for fibroblasts which has 
been previously implicated in fibrosis (Perugorria et al., 2008; Shoyab et al., 1989; Zhou et 
al., 2012), was also significantly upregulated (Figure 10). However, we were unable to 
detect any change in the expression of transforming growth factor beta (Tgfb1), a major 
driver of fibrosis in the heart and other tissues (Fan et al., 2012).  
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Figure 9. Relative weights of C57BL6 male mice hearts after 4 weeks of oral 
administration with water or sunitinib 80 mg/Kg. Relative heart weights (Heart (g)/BW(g)) 
are expressed as the ratio between heart weight vs the body weight (BW) of the animal. The 
graph shows the means and standard errors.  
 
 
  
 50 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Relative transcript levels of hypertrophy- and remodeling-related genes in the 
left ventricle of C57BL/6 male mice after 4 weeks of treatment with water (control) or 
sunitinib 80mg/Kg. The data was generated by qPCR; the graph shows the means and 
standard errors. The genes evaluated were cytochrome P450, family 1, subfamily a, 
polypeptide 1 (Cyp1a1), fibroblast growth factor 21 (Fgf21), amphiregulin (Areg), 
transforming growth factor beta 1 (Tgfb1) and collagen type I alpha 1 (Col1a1). The 
asterisks denote statistical significant differences between the sunitinib-treated and control 
groups as determined by Student’s t-test, (*) p < 0.05.   
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Figure 11. Masson's trichrome staining of cardiac tissue from representative C57BL/6 male mice orally administered vehicle (C) or 
sunitinib 80 mg/Kg for 4 weeks (S1 and S2). Collagen accumulation appears stained in blue. Scale bars are 100 µm (left panel), 50 µm 
(central panel) and 25 µm (right panel). 
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Mitochondrial dysfunction has a well-known role in cell and tissue injury, inflammation 
and remodeling (Kumar et al., 2013). Previous studies performed in humans, mice and 
cultured cardiomyocytes have reported that sunitinib induces mitochondrial damage 
(Kerkela et al., 2009; Monsuez et al., 2010). This is an specially important aspect of the 
deleterious effects of sunitinib, not only due to the toxic nature of mitochondrial injury but 
also because of the crucial role of the mitochondria in the coordination and functioning of 
cellular energy metabolism, to which the heart is particularly sensitive (Finck, 2007; Jaswal 
et al., 2011; Scolletta and Biagioli, 2010). Defects in mitochondrial biogenesis and function 
are thought to underlie energetic alterations in cardiovascular pathophysiology (Rimbaud et 
al., 2009; van Bilsen et al., 2004).  
  
Ultrastructural analysis of left ventricular sections by transmission electron microscopy 
showed clear signs of cardiomyocyte damage in sunitinib-treated animals. Figure12 shows 
the appearance of empty cytoplasmic spaces between cardiac myofibrils as well as altered 
mitochondria with ruptured membrane and partial loss of mitochondrial matrix. In addition, 
Figure 13 shows the appearance of septae in the mitochondria, an event typically seen in 
skeletal and cardiac muscle injury (Duncan and Shamsadeen, 1991). Although myofibrils 
were well oriented and the sarcomere were properly defined (Figure 14A), we observed 
numerous degenerated, swollen mitochondria with reduced or vanished matrix and effaced 
cristae (Figure 14B) as well as an abundance of intra-mitochondria membranes whorls. 
Numerous sarcoplasmatic lipid droplets were also detected, in close contact with adjacent 
mitochondria (Figure 15).  
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Figure 12. Transmission electron micrograph of the left ventricle of C57BL6 male mice after 4 weeks of treatment with water (A) or 
sunitinib 80mg/kg (B). Mitochondria (M), myofibrils (MF), Z line (Z). The arrows indicate broken mitochondria with reduced or 
vanished matrix and disrupted crests. Arrow heads show cytoplasmic voids between the cardiac myofibrils.   
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Figure 13. Transmission electron micrograph of the left ventricle of C57BL6 male mice after 4 weeks of treatment with vehicle  (A) 
or sunitinib 80mg/kg (B). Mitochondria (M). The arrows indicate a mitochondrial septum. Arrow head shows a zone of cytoplasmic 
loss. 
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Figure 14A. Transmission electron micrograph of left ventricle from C57BL6 male mice after 4 weeks of 
treatment with sunitinib 80mg/kg. Degenerating mitochondria (DM) and lipid droplets (Ld) are indicated. The 
arrows indicate intra-mitochondria membrane whorls. Arrow heads point to vanished mitochondrial matrix. 
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Figure 14B-C. Transmission electron micrograph of the left ventricle of C57BL6 male mice after 4 weeks of treatment with sunitinib. 
Degenerating mitochondria (DM) and lipid droplets (Ld) are indicated. The arrows indicate intra-mitochondria membrane whorls. 
Arrow heads point to regions of vanished mitochondrial matrix.
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      Figure 15. Transmission electron micrograph of left ventricle of C57BL6 male mice 
      after 4 weeks of treatment with sunitinib. Lipid droplets (Ld) are indicated.  
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The ultrastructural mitochondrial alterations revealed by transmission electron microscopy 
indicated the possibility of generalized mitochondrial dysfunction in sunitinib-treated 
animals. Since perturbations of cardiac energy metabolism are a significant factor in 
cardiac myopathies (Finck, 2007), we evaluated the relative expression of a selected group 
of genes involved in cellular and mitochondrial function and energy metabolism (Table 1). 
We targeted genes coding for important components of the mitochondrial electron transport 
chain complexes III and IV, fatty acids transport and oxidation as well as proteins involved 
in cellular glucose transport and metabolism. In addition, several transcription factors with 
described key roles in the control of substrate metabolism were also studied. 
 
The gene expression analyses in Figure 16 show no changes in the relative expression of 
Cox4i1, Cox5b and Uqcrc1, involved in mitochondrial respiration, suggesting that 
expression of those genes was insensitive to our 4-weeks sunitinib treatment. However, the 
expression of Ucp2 and Ucp3 decreased in treated animals, reaching significant levels for 
Ucp3. These genes code for the uncoupling proteins 2 and 3 respectively, which are 
members of the anion carrier proteins superfamily present in the inner mitochondrial 
membrane and which regulate mitochondrial membrane potential, and therefore, ATP 
synthesis and reactive oxygen species (ROS) production (Laskowski and Russell, 2008; 
Perrino et al., 2013). Reduction in the levels of UCP3 can lead to exacerbated ROS 
production and cardiomyocyte damage (Perrino et al., 2013). 
 
Out of the genes tested involved in substrate metabolism (Figure 17) neither the glucose  
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Figure 16. Relative transcript levels of mitochondrial genes in the left ventricle of 
C57BL/6 male mice after 4 weeks of treatment with water (control) or sunitinib 80mg/Kg. 
The data was generated by qPCR; the graph shows the means and standard errors. The 
genes evaluated were cytochrome c oxidase subunit IV isoform 1 (Cox4i1), cytochrome c 
oxidase subunit Vb (Cox5b), ubiquinol-cytochrome c reductase core protein 1 (Uqcrc1), 
uncoupling protein 2 (Ucp2) and uncoupling protein 3 (Ucp3). The asterisks denote 
statistical significant differences between the sunitinib-treated and control groups as 
determined by Student’s t-test, (***) p < 0.001.   
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Figure 17. Relative transcript levels of metabolism-related genes in the left ventricle of C57BL/6 male mice after 4 weeks of 
treatment with water (control) or sunitinib 80mg/Kg. The data was generated by qPCR; the graph shows the means and standard 
errors. The genes evaluated were solute carrier family 2 (facilitated glucose transporter), member 4 (Slc2a4), solute carrier family 27 
(fatty acid transporter), member 1 (Slc27a1), peroxisome proliferator activated receptor alpha (Ppara), peroxisome proliferator 
activator receptor delta (Ppard), peroxisome proliferative activated receptor, gamma, coactivator 1 alpha (Pgc1a), carnitine 
palmitoyltransferase 1b (Cpt1b) acyl-Coenzyme A dehydrogenase, medium chain (Acadm), CD36 antigen (Cd36) and pyruvate 
dehydrogenase kinase, isoenzyme 4 (Pdk4). The asterisks denote statistical significant differences between the sunitinib-treated and 
control groups as determined by Student’s t-test, (*) p < 0.05).   
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transporter Slc24a (Glut4), the fatty acid transporter Slc27a1 nor the peroxisome 
proliferator activated receptors alpha and delta (Ppara and Ppard) showed any expression 
changes. Cpt1b and Acadm were moderately (but non-significantly) downregulated. 
CPT1B is the main long-chain fatty acid transporter in cardiomyocyte's mitochondrial 
external membrane and is the rate-limiting step in mitochondrial β-oxidation (He et al., 
2012). Acadm codes for MCAD, an acyl-coenzyme A dehydrogenase essential for the 
oxidation of medium-chain fatty acids (Spiekerkoetter and Wood, 2010). Only Pgc1a, 
CD36 and Pdk4 displayed an statistically significant alteration of expression. PGC1alpha is 
a co-activator of transcription that is fundamental for the selection of substrate utilization in 
the heart and has been found downregulated in heart failure in humans and animal models 
(Aubert et al., 2013). CD36 is a fatty acid transporter responsible for 40-60% of the cellular 
fatty acid uptake and a reduction on its cellular level can lead to the preferential use of 
glucose as a source of energy (Guzzardi and Iozzo, 2011). PDK4 (pyruvate dehydrogenase 
kinase 4) inhibits the conversion of pyruvate to acetyl-CoA and promotes the utilization of 
fatty acids as energy source. Conversely, if PDK4 levels are decreased, the use of glucose 
over fatty acids can be favored (van Bilsen et al., 2004).  
 
These gene expression analyses suggest that the cardiac metabolism of fatty acids is being 
negatively affected in the sunitinib-treated group possibly promoting the occurrence of a 
metabolic switch in energy substrate utilization. That, together with the induction of tissue 
damage, inflammation and mitochondrial injury, indicate that the sunitinib treatment 
schedule and dosage used in the mouse model described here generated cardiac toxicity. 
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4.3. Evaluation of sunitinib-induced cardiac toxicity using PET 
Alterations in myocardial function and energy metabolism are distinctive caracteristics of 
multiple cardiac diseases (Gropler, 2013; Herrero et al., 2007; Tokarska-Schlattner et al., 
2006). Among the most common perturbations recognized in the course of heart disease are 
decreases of the LVEF and modifications in the usage of glucose or fatty acids as the main 
energy substrate (Jaswal et al., 2011). To explore the ability of PET to detect those signs of 
cardiotoxicity in our animal model, we performed 11C-acetate and FDG PET imaging at 
days 0 and at days 6th or 7th of each week of treatment. 11C-acetate was used to estimate 
MVO2 as a reflection of the overall oxidative metabolism given the close connection 
between the tricarboxylic acid and oxidative phosphorylation (Peterson and Gropler, 2010). 
MVO2 is a fundamental indicator of systolic functions such as heart rate, contractile state, 
and wall stress (Knaapen et al., 2007). We also utilized 11C-acetate to measure the MBF, as 
a strong correlation between the relative uptake of 11C-acetate with the relative MBF has 
been described (Jiji et al., 2012; Klein et al., 2001), and changes in MBF are associated 
with important perturbations in cardiac metabolism (Di Carli et al., 2000). 
 
K1 and K2 values, representing MBF and MVO2, respectively, were extracted using a three 
compartment kinetic analysis applied to PET 11C-acetate dynamics. There were no 
statistically significant differences between treated animals with the pre-treatment values 
(Figure 18), except an unexplained difference for MVO2 between pretreatment and scan 1. 
Furthermore, no differences in MBF and MVO2 were observed between controls and 
animals treated with sunitinib during the 4 weeks of the study (Figure 18). These results  
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Figure 18. (A) Myocardial blow flow values (MBF) expressed as K1 and (B) myocardial 
oxygen consumption (MVO2) represented as K2. Both variables were estimated from a 
three compartment kinetic analysis for 11C-acetate obtained from C57BL6 male mice at 
pre-treatment and scans done each of four weeks of treatment with sunitinib (80mg/Kg). 
The graphs show the means and standard errors. 
  
A
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indicate either that there are not detectable perturbations in myocardial perfusion (K1) and 
oxygen consumption (K2), or that the PET protocol used in this study is unable to detect 
them. 
 
The FDG influx constant (Ki) was determined by PET, as a measurement of myocardial 
glucose uptake. The mean Ki values obtained using Patlak analysis are shown in Figure 19. 
No significant differences were found either between pre- and post-treatment neither 
between control and sunitinib-treated groups. These results suggest that there are not 
detectable changes in myocardial glucose uptake as a consequence of the sunitinib 
treatment schedule used in our study. 
 
Non-radioactive blood glucose levels are required to calculate the MMRG (Zhong et al., 
2013). Blood glucose levels were determined by glucometer measurements right before the 
PET scans, the values obtained are shown in Figure 20. No differences were detected 
between the two groups or within each group. The values of Ki and blood glucose were 
used to calculate MMRG using Patlak analysis. The result shown in Figure 21 demonstrate 
that there are no significant differences in the metabolic rate of glucose between the 
controls and the sunitinib-treated animals. 
 
In the clinical monitoring of cardiotoxicity and heart failure, the LVEF is used as the initial 
indicator of left ventricular dysfunction (Witteles et al., 2011). PET imaging in a 
syncronized dynamic gated acquisition with FDG was used to measure LVEF. Figure 22 
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Figure 19. Myocardial FDG uptake (Ki) for control and sunitinib-treated (80mg/Kg) 
C57BL/6 male mice. Data was obtained at pre-treatment and scans done each of four weeks 
of treatment with sunitinib. The graph shows the means and standard errors. 
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Figure 20. Blood glucose levels for control and sunitinib-treated (80mg/Kg) C57BL/6 male 
mice. Data was obtained at pre-treatment and scans done each of four weeks of treatment 
with sunitinib. The graph shows the means and standard errors. 
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Figure 21. Myocardial metabolic rate of glucose (MMRG) for control and sunitinib-treated 
(80mg/Kg) C57BL/6 male mice. Data was obtained at pre-treatment and scans done each of 
four weeks of treatment with sunitinib. The graph shows the means and standard errors. 
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Figure 22. Cardiac images of C57BL6 male mice treated with sunitinib 80 mg/kg, 30 minutes after intravenous administration of 13.3 
MBq of FDG. The images shown were obtained from a synchronized acquisition with the mouse electrocardiogram signal. AVG = 
average; ED = end of diastole; ES = the end of systole. 
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shows the cardiac images obtained with a sequence of images synchronized into eight 
electrocardiogram gates for a representative mouse from the sunitinib-treated group. The 
data obtained in these curves are used to generate the ejection fraction values. The pre-
treatment LVEF values fell within the range reported for mice in previous studies 
(Lightfoot et al., 2010; Stegger et al., 2009; Zhong et al., 2013) and did not differ between 
the two groups (Figure 23). Throughout the experiment, the LVEF values were stable in the 
control group and no significant differences were found when compared against the pre-
treatment values (Figure 23). However, sunitinib-treated mice showed a significant and 
progressive decrease in LVEF with respect to the control group, starting the first week of 
treatment. The average LVEF fell from a pretreatment value of 74.43 ± 0.9 % to 63.60 ± 
2.0% at the end of the fourth week of treatment with a maximum drop of 10.83 %. These 
results reveal that the sunitinib treatment used in this study cause cardiac toxicity evidenced 
by a significant reduction in the LVEF and detectable by FDG-PET imaging.  
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Figure 23. Left ventricle ejection fraction (LVEF) of C57BL6 male mice at 0 (pre-
treatment), 1, 2, 3 and 4 weeks of treatment with sunitinib 80mg/Kg. LVEF were obtained 
by cardiac PET imaging in a syncronized dynamic gated with FDG. The graph shows the 
means and standard errors. The asterisks denote statistical significant differences between 
the sunitinib-treated and control groups as determined by Student’s t-test, (*) p < 0.05), 
(**) p < 0.01) and (***) p < 0.001).   
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5. DISCUSSION 
 
Cardiovascular diseases and cancer are the two leading causes of death by non-
communicable diseases in high-income countries (World Health Organization). In Canada, 
they accounted for 49.6% of all deaths in 2011 (Statistics Canada, 2014). Ironically, many 
therapies that offer a higher chance of survival to cancer patients, have the side effect of a 
significant risk for cardiac toxicity and the development of cardiac clinical conditions. As 
heart failure is the ultimate fate of cardiac damage, this is an important complicating aspect 
of anti-cancer therapies, for which a solution is urgently needed. 
 
Sunitinib has been a succesful anti-cancer drug, however, it can induce symptomatic grade 
3 or 4 heart failure as early as 22 days after the initiation of treatment (Telli et al., 2008). In 
fact, cardiac damage is the top-second reason for interruption of sunitinib treatment 
(Witteles and Telli, 2012). In spite of significant efforts, it is not yet fully understood what 
renders some patients at risk of cardiac toxicity while others are rather unaffected (Abdel-
Aziz, 2011). The biological complexity of cardiac physiology and metabolism pose a 
tremendous challenge for the detection of toxicity before it becomes symptomatic. In this 
regard, PET remains as one of the best monitoring alternatives due to its non-invasive 
nature and its recognized ability to probe metabolic aspects of myocardial function (Ong et 
al., 2014). However, PET protocols to detect early signs of toxicity and predict or avoid 
symptomatic heart damage are far from optimal in clinical practice. 
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In this study, we explored the use of 11C-acetate and FDG PET for the early detection of 
cardiac metabolic and functional alterations during treatment with sunitinib. We utilized a 
mouse model of short-term sunitinib administration, which we characterized for several 
biological parameters, along with the ability of PET to detect changes in myocardial blood 
flow, oxygen consumption, glucose uptake, glucose utilization and left ventricular ejection 
fraction. Our PET results showed no significant changes in myocardial blood flow, oxygen 
consumption, glucose uptake or glucose utilization but we detected a significant and 
progressive reduction in the LVEF.  
 
5.1. Cardiac contractile dysfunction 
In this study, the LVEF fell since the first week of treatment, with a maximum drop of 
10.83% at week four. Decreases of LVEF values have been recorded in 8-33% of patients 
treated with sunitinib (Blasi et al., 2012; Di Lorenzo et al., 2009; Mellor et al., 2011; 
Monsuez et al., 2010; Rainer et al., 2012; Richards et al., 2011; Steingart et al., 2012; 
Zambelli et al., 2011). A rapid onset of LV dysfunction (as the one observed by us) has 
been reported, sometimes with inconstant reversibility (Mellor et al., 2011; Monsuez et al., 
2010), possibly explained by the two weeks off-treatment built into each cycle of four 
weeks-on/two weeks-off regularly used in the clinics. Although no specific guidelines have 
been established regarding LVEF drops, the clinical definition of cardiotoxicity produced 
by the Cardiac Review and Evaluation Committee that supervised the trastuzumab clinical 
trials (Seidman et al., 2002) has become the de facto standard (Albini et al., 2010; Gillespie 
et al., 2011; Wells and Lenihan, 2010). It considers a fall of LVEF to under a 55% absolute 
level, or a 10% decline as indicators of drug-induced cardiac toxicity (Seidman et al., 
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2002). Moreover, according to new criteria of common terminology for adverse events 
recommended by Stanford Cardiology, a LVEF drop between 10%-19% is considered as 
left ventricle sytolic dysfuction and grade 2 heart failure (Witteles et al., 2011). Our results 
at the fourth week of treatment showing a decrease of over 10% in the LVEF are then 
indicative of cardiac toxicity after only one cycle of treatment. 
  
The mechanisms of sunitinib-associated left ventricular dysfunction are not fully known. It 
is thought that it results from direct cardiomyocyte toxicity (Cohen et al., 2011) 
exacerbated by hypertension (Hutson et al., 2008). However, not all the patients that 
develop left ventricular dysfunction suffer from hypertension (Force and Kolaja, 2011), 
thus this association has been challenged and remains controversial (Mellor et al., 2011; 
Rini, 2007). Nevertheless, high blood pressure has been reported in multiple studies of 
sunitinib treatment (Chu et al., 2007; Di Lorenzo et al., 2009; Mellor et al., 2011); such 
hypertension is seen as the result of the anti-angiogenic effect of the drug, which ultimately 
leads to a decrease in capillary density and an increase of peripheral vascular resistance 
(Aparicio-Gallego et al., 2011; de Boer et al., 2010; Inai et al., 2004). Some authors have 
suggested that the etiology of hypertension may be also related to direct sunitinib renal 
toxicity and dysfunction, as hematuria (blood in the urine, reflective of renal damage) and 
nephrotic syndrome have been reported during therapy with sunitinib (Mori et al., 2010; 
Takahashi et al., 2012; Zhu et al., 2009). This is probably aggravated in patients with renal 
cell carcinoma (a patient population to which sunitinib is commonly administered) since 
they present a high (65.6%) prevalence of renal dysfunction. 
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Throughout our study, we did not detect blood in the urine, suggesting that the sunitinib 
dose and administration schedule used here did not induced significant renal damage in 
mice. We did not find blood pressure differences between treated and control groups, even 
though there was a significant LVEF drop. This suggests that (at least in our mouse model) 
there is not a clear relationship between hypertension and LVEF decrease. Similar results 
have been reported in some studies in humans (Chu et al., 2007; Telli et al., 2008) and a 
previous study using C57BL/6 mice treated with sunitinib at 40 mg/kg/day during 3 weeks, 
which failed to show any elevation of blood pressure that could be associated with cardiac 
dysfunction (Chintalgattu et al., 2013).  
 
5.2. Cardiac tissue injury 
LVEF is a functional parameter that can be affected by structural tissue damage. The 
histological assessment of our cardiac tissue samples showed only moderate pathological 
changes, which may nonetheless, be contributing to dysfunction. The nature of myocardial 
tissue injury during RTK inhibitor treatments has been poorly investigated and remains 
largely undefined (Schmidinger et al., 2008). Some data with RTK inhibitors that have 
been cardiotoxic in the clinic have shown no evidence of cardiac tissue damage in studies 
with animals, using routine histological examination (Yang and Papoian, 2012). On the 
other hand, heart lesions such as myocardial vacuolation and pericardial inflammatory 
infiltrates have been noted in rat models (French et al., 2010; Maayah et al., 2014; Mellor et 
al., 2011). We found mild fibroplasia with hemosiderophages, consistent with chronic 
microhemorrhage as well as abundant myofiber vacuolation and signs of early muscle 
degeneration with possible intracellular edema. Clear signs of inflammation and tissue 
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remodeling were also found, evidenced by the elevation of local gene expression of pro-
inflammatory mediators, the infiltration of neutrophils into the cardiac tissue, the 
upregulation of genes involved in tissue remodeling and wound healing, and the deposition 
of collagen. 
 
Inflammation is a protective mechanism that can be triggered by tissue injury, including in 
sterile conditions (Chovatiya and Medzhitov, 2014). It leads to the secretion of pro-
inflammatory mediators such as TNFα, IL1β, nitric oxide (NO), etc; these mediators have 
been shown to be relevant in the context of heart damage (Hedayat et al., 2010). TNFα 
(whose gene we found upregulated) has been implicated in tissue damage (Yang et al., 
2013) and reduction of cellular ATP (Spector et al., 2007), and it plays a key role in 
depression of myocardial contractility (Hedayat et al., 2010). IL1β (also upregulated in our 
study) exacerbates contractile dysfunction in synergism with TNFα, by promoting calcium 
leak from the sarcoplasmic reticulum, and together with other proinflammatory cytokines, 
induces the expression Nos2 and the production of NO by cardiac myocytes (Bracey et al., 
2013; Hedayat et al., 2010). Interestingly, the expression of IL6, a cytokine previously 
reported to both improve and deteriorate cardiovascular performance (Hedayat et al., 2010), 
is downregulated. The reason(s) for Il6 downregulation and the potential biological 
significance of it are unclear. 
 
The increased expression of several pro-inflammatory factors can help explaining the 
structural (tissue injury) and functional (decreased LVEF) damage seen in our sunitinib-
treated animals. In fact, since the postulation of the "cytokine hypothesis" by Seta et al. in 
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1996 (Seta et al., 1996), the role of inflammation in heart damage has been well established 
and it is widely viewed today as a central contributor to the pathogenesis and progression 
of heart failure (Hedayat et al., 2010). Injury and inflammation are inextricably linked and 
typically trigger a remodeling response characterized by extracellular matrix deposition. If 
sustained, this response may evolve into fibrosis, which represents a major 
pathophysiological trait of harmful left ventricular remodeling and constitute a hallmark 
feature of the hypertrophic response (Aoyagi and Matsui, 2011; Strayer and Rubin, 2014).  
 
The vast majority of cells in the heart are fibroblasts (Aoyagi and Matsui, 2011), they are 
also the main source of cardiac fibrillar collagen. Alterations in collagen abundance, 
isoforms, cross-linking patterns and recycling have been shown to play a key role in 
cardiac remodeling and progressive LV dysfunction (Hedayat et al., 2010), possibly by 
increasing muscle stiffness and interfering with systolic contraction and diastolic 
relaxation, as well as impairing diffusion of oxygen and nutrients (Ho et al., 2014; Strayer 
and Rubin, 2014). Fibrosis can also lead to remodeling of electrical conduction pathways in 
the heart, which is a major factor in the pathogenesis of cardiac arrhythmias (e.g., atrial 
fibrillation and ventricular tachycardia), which are some of the cardiac adverse effects 
reported by sunitinib treatment in humans (Bello et al., 2009; Strayer and Rubin, 2014). We 
observed an increase in Col1a1 gene expression and interstitial collagen deposition, a 
typical feature of myocardial injury (Lipshultz et al., 2013). Accompanying these, the 
expression of Areg, an EGFR ligand involved in the response to tissue mechanical loading 
in cardiomyocytes, fibroblasts, and vascular smooth muscle (Ye et al., 2013) was 
upregulated, as well as Cyp1a1, a marker of hypertrophy (Maayah et al., 2014), whereas 
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Fgf21, a cardio-protective fibroblast growth factor (Planavila et al., 2013), was 
downregulated. Surprisingly, the expression of the gene coding for TGFB1, a recognized 
factor in the development of fibrosis (Fan et al., 2012), was only slightly upregulated. 
 
The results from FDG-PET clearly demonstrated that in the model used in this study, there 
is a significant fall of the LVEF detectable from the first week of treatment with sunitinib, 
which did not correlate with hypertension or renal damage. The microscopy and gene 
expression analyses performed here suggest that an emerging fibrosis/hypertrophy process 
is underway after four weeks of treatment but we are lacking data for the first weeks. The 
larger decrease on the LVEF at week four strongly suggests that these alterations are 
actively contributing to LV dysfunction at that time. However, given the time required for 
the development of fibrosis and hypertrophy, we believe it unlikely that they are major 
factors to LV dysfunction at the early phases of treatment.  
 
In contrast to fibrosis and hypertrophy, the direct pharmacological effect of sunitinib over 
the activity of a wide range of cellular processes is more immediate. Sunitinib is known to 
cause hypothyroidism as early as 2 weeks after initiation of treatment (Collinson et al., 
2011; Girardi et al., 2010; Kappers et al., 2011). The resulting reduction of triiodothyronine 
(T3) levels impacts the expression of cardiac sodium-potassium adenosine triphosphatase 
(Na-K-ATPase) (Kamitani et al., 1992; Schmidinger, 2013) which may render the  
cardiomyocytes unable to maintain an adequate ionic balance leading to progressive 
intracellular water accumulation, cell swelling, vacuolation and damage. Also, the 
reduction of T3 can lead to myocardial systolic and diastolic dysfunction by affecting the 
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expression of the sarco(endo)plasmatic reticulum cardiac ion pump SERCA2A (Ca2+-
ATPase exchanger), which regulates cardiac contraction and relaxation by controlling the 
intracellular concentration of Ca2+ (Force and Kolaja, 2011; Muller et al., 2003; 
Schmidinger, 2013).  As we did not evaluate these parameters, we can not provide an 
assessment of whether they were contributing factors to the observed LV dysfunction. 
 
5.3. Cardiac metabolism 
Sunitinib inhibits the AMP-activated protein kinase (AMPK), a central regulator of cellular 
metabolism and ATP utilization (Greineder et al., 2011; Schmidinger et al., 2008). In the 
presence of sunitinib, ATP binding to AMPK is blocked and therefore it is unable to 
transfer ATP to substrates, interfering with the activation of energy-conserving 
mechanisms and aggravating energy depletion (Kerkela et al., 2009). ATP concentration 
has been previously found significantly reduced in cardiomyocytes exposed to sunitinib 
(Hohenegger, 2012). This is hardly surprising considering the inhibition of AMPK and the 
profound structural and functional mitochondrial abnormalities uncovered in patients and in 
treated cardiac cells in culture (Kerkela et al., 2009). Compelling evidence suggests that 
increased mitochondrial damage and dysfunction are a common denominator in 
cardiovascular disease development (Ballinger, 2005). The mitochondrial alterations 
reported in the literature include swelling, loss of normal architecture, disruption of cristae, 
cavitation of matrix and increased number of electron-dense matrix deposits (French et al., 
2010; Kerkela et al., 2009; Montaigne et al., 2012). We found similar mitochondrial 
injuries in samples from sunitinib-treated animals after four weeks of treatment, which 
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support the notion of cellular and mitochondrial damage and it is suggestive of 
abnormalities in cardiac energy metabolism.  
 
Perturbation of cardiac energy metabolism has multiple consequences including a reduction 
in the capacity and efficiency of mitochondrial respiration and ATP production (Aubert et 
al., 2013). We found a decrease in the expression of the uncoupling proteins Ucp2 and 
Ucp3, two critical enzymes directly involved in mitochondrial ATP production, Ca2+ 
uptake and fatty acid utilization (Essop et al., 2004; Laskowski and Russell, 2008; Perrino 
et al., 2013; Safari et al., 2014). UCPs levels are decreased by the known cardiotoxic drug 
doxorubicin (Perrino et al., 2013) and are often reduced in heart failure in humans and 
animal models (Laskowski and Russell, 2008). The lower expression of Ucp2 and Ucp3 
may be an indication of decreased ATP production in sunitinib-treated hearts.  
 
Myocardial metabolism has the ability to switch from utilization of its main substrate 
(long-chain fatty acids, (Kuge et al., 2008; Neely et al., 1972)) to glucose in response to 
myocardial injuries such as hypertrophy, ischemia and heart failure (Jaswal et al., 2011). 
While this metabolic switch initially serves an adaptive function, long-term inhibition of 
the major source of energy leads to an energetic compromised heart with diminished 
functional capacity and eventually, progression to heart failure (Dyck and Lopaschuk, 
2006). The expression profile of mitochondrial and metabolic genes that we observed in the 
sunitinib-treated mice hints to some defect in the metabolism of fatty acids as Cd36, Pdk4 
and Pgc1a genes were significantly downregulated, and other relevant genes (Cpt1b, 
Acadm) showed a slight, non-significant decrease. Although these results should be taken 
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with caution because we tested only a fraction of the relevant genes and studied regulation 
only at the transcriptional level, there is a trend to a lower expression that could be 
indicative of emerging fatty acid metabolic defects. This interpretation is further supported 
by the correspondence of our observations with published results showing that the adaptive 
switch of the injured heart to a preferential use of glucose aiming to maximize efficiency, is 
characterized by the downregulation of pyruvate dehydrogenase kinase isoforms (PDKs), 
uncoupling proteins (UCPs) and carnitine palmitoyltransferase-1 (CPT-1) (Ardehali et al., 
2012). 
 
However, we did not find indications by FDG-PET of an increase in glucose consumption, 
(MMRG) as it should have been expected. To determine MMRG, the blood glucose levels 
and Ki are required. Neither Ki nor the levels of blood glucose showed any change, for any 
group. An increase in Ki was anticipated because it has been reported to occur in the 
presence of contractile dysfunction (Sen et al., 2013). Furthermore, the relative expression 
of Slc2a4 (GLUT4), a regulator of glucose uptake and the major glucose transporter 
isoform in the heart (Heather et al., 2013; Postic et al., 1994; Santalucia et al., 1999; 
Santalucia et al., 1992) was also expected to increase because substrate transport across the 
sarcolemma is the first regulated step in cardiomyocyte substrate metabolism (Heather et 
al., 2013) and the expression of this glucose transporter has been found increased when 
myocardial glucose utilization is promoted (Hamblin et al., 2009). Conversely, a reduced 
glucose uptake has been related with decrease levels of Slc2a4 (Murray et al., 2006). 
Nonetheless, the Slc2a4 gene was not upregulated in the animals under sunitinib 
administration, supporting the PET observation of a lack of increase in glucose utilization. 
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Moreover, we did not find changes in MVO2 or MBF, which typically accompany the 
slowing down of cardiac fatty acid metabolism. Oxygen consumption is related to energy 
expenditure, (the amount of energy consumed from the substrate) (Guitierrez and 
Theodorou, 2012) and the ability of the heart to match oxygen supply to demand is a 
fundamental principle of myocardial flow regulation (Tawakol et al., 2003). Given our 
findings of a lowered LVEF in the treated group, and considering previous demonstration 
that the contractile state of the myocardium determines MVO2 (Schwaiger and Wolpers, 
1990), we predicted a reduction of MVO2. It was asumed that sunitinib-induced contractile 
dysfunction (shown by decreased LVEF) would correlate with a metabolic switch with 
lower MVO2 levels reflecting distortions in the oxidative metabolism but paradoxically, 
MVO2 and MBF levels did not change with sunitinib treatment. 
 
The reasons for these findings are unclear. The treatment used in this study was clearly 
toxic to animals as shown by hypoactivity, lower body weight and lower food 
consumption, all previously reported effects of sunitinib (Hipp et al., 2008; Tanaka et al., 
2011). In addition, the histopathology, immunostaining and electron microscopy showed 
clear signs of structural cardiac damage. The fact that PET was able to reveal LVEF drops 
but failed to uncover any changes in MMRG, MVO2 or MBF indicates the possibilities that 
those changes are not present or escaped detection by PET, as performed in this study. Our 
findings resemble what is known in cardiology as "stunned myocardium", a postischemic 
condition characterized by contractile dysfunction with normal perfusion and normal FDG 
uptake (Medical Advisory Secretariat, 2005). Stunning is a reversible condition that 
precedes the more severe "hibernating myocardium"; in hibernation, there is reduced 
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perfusion, contractile dysfunction, alteration of structural proteins and metabolism, 
cytoskeleton disorganization, myofilaments loss and sarcomeric instability 
(Anagnostopoulos et al., 2013; Medical Advisory Secretariat, 2005). Continuous or 
repetitive stunning can lead to hibernation and differentiating between them is complicated 
because they may coexist (Medical Advisory Secretariat, 2005). It can be speculated that 
early during treatment, sunitinib induces cardiac stunning and as the treatment progresses 
stunning evolves to a more severe and distinctive damage that involves clear metabolic 
dysfunction. This is a reasonable scenario, given our results and the fact that sunitinib 
induces the generation of oxygen radicals and disturbances of cellular Ca2+ homeostasis 
(Rainer et al., 2012), which are also considered the most plausible molecular bases of 
cardiac stunning (Bolli and Marban, 1999). 
 
Yet, another revealing finding supports the idea of perturbations in the metabolism of fatty 
acids. Normally, cardiac myocytes do not accumulate lipid droplets, reflecting a finely-
regulated equilibrium between lipid uptake and oxidation (Ge et al., 2012; Goldberg et al., 
2012; van Herpen and Schrauwen-Hinderling, 2008). However, when the rates of uptake, 
synthesis and utilization are mismatched, the excess lipid is stored in cytoplasmic droplets 
(Goldberg et al., 2012; Olofsson et al., 2009). Impairment of cardiac fatty acid oxidation 
leads to intracellular lipid accumulation, which eventually becomes cytotoxic (Finck, 2007; 
Goldberg et al., 2012). Cardiac lipid accumulation, especially long-chain fatty acids, has 
been associated with contractile dysfunction (Abel, 2011; Fountoulakis et al., 2005; Park et 
al., 2007). Intracellular lipid deposit has been documented in heart biopsies from patients 
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treated with imatinib, another RTK inhibitor (Kerkela et al., 2006). We reported here that 
sunitinib induces accumulation of cytosolic lipid droplets in cardiomyocytes. 
 
Being a multi-targeted RTK inhibitor, sunitinib binds to multiple cellular kinases (Fabian et 
al., 2005; Karaman et al., 2008) and has the potential to be cytotoxic in many different 
ways, in fact, it is thought that it has both on-target and off-target side effects (Force and 
Kolaja, 2011). That, together with our results, opens the possibility that the onset of LV 
dysfunction induced by sunitinib may occur in the absence of overt myocardial metabolic 
perturbation, at least at early stages of treatment. We performed treatment for only four 
weeks, thus it is possible that metabolic alterations had just begun to emerge and a longer 
treatment is required for them to be significant in this mouse model. 
 
The biochemical mechanisms underlying the cardiotoxicity of RTK inhibitors remain 
poorly understood (Hall et al., 2013). Energy metabolism perturbations are widely accepted 
as major drivers of contractile dysfunction and heart failure (Huss and Kelly, 2005; Turer et 
al., 2010), but they are not considered the only cause of it. Other factors such as 
abnormalities in excitation-contraction coupling (arrhythmias, considered as one of the 
most serious immediate cardiac functional abnormalities), perturbations in the physiology 
of Ca2+, and alterations in the synthesis and concentration of reactive nitrogen and oxygen 
species, which may lead to cellular damage, can also play a role (Berridge et al., 2013; 
Dasanu et al., 2012; Davies et al., 1996; Giordano, 2005; Hare and Stamler, 2005), more so 
considering that sunitinib for example, induces the generation of oxygen radicals and 
disturbances of cellular Ca+2 homeostasis (Rainer et al., 2012).  
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In summary, using FDG-PET, we documented early LV dysfunction (shown by a drop in 
the LVEF) in a mouse model of 5 days-on/two days-off sunitinib administration of 80 
mg/Kg/day for four weeks. LV dysfunction did not correlate with hypertension, neither 
with changes in MMRG, MVO2 or MBF during the time of the study, as determined by 
FDG- and 11C-acetate-PET. Our results illustrate the biological complexity of the 
myocardial damage induced by sunitinib and highlight the need of further studies to 
understand its molecular bases and devise effective ways for its early detection. 
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6. CONCLUSIONS 
 
Sunitinib is typically administered to patients in repeated cycles of 4 weeks-on/two weeks-
off treatment, at doses of 50 mg/day. Administration is done every day during the 4 weeks 
on treatment. Cardiac damage has been observed in patients at different time points of the 
therapy, this together with the poor understanding of the pattern of events leading to 
toxicity, makes the prediction of whether and when the treatment will become cardiotoxic 
extremely difficult. Here we demonstrate that sunitinib administration of 80 mg/kg/day 
during 5 days per week, for 4 weeks caused cardiac toxicity in C57BL6 male mice, which 
makes it a useful model for the in vivo study of the mechanisms leading to the onset of 
cardiac damage. 
 
In our model, sunitinib administration triggered LV dysfunction as early as one week after 
the beginning of treatment. This dysfunction was detected by FDG-PET and was 
manifested by a significant decrease of the LVEF, with a relative drop of more than 10% at 
the 4th week of treatment. According to current classifications to evaluate drug-induced 
cardiac toxicity, this damage can be classified as grade-2 heart failure, which would 
indicate the need for further intervention during sunitinib clinical use. 
 
Contractile dysfunction is almost invariably associated with perturbations in myocardial 
metabolism that cause defects in ATP production and lead to energetic stress. These defects 
can be reflected as changes in glucose metabolism, fatty acid metabolism and oxidative 
metabolism, which can be investigated using PET. Under the hypothesis that during 
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sunitinib treatment metabolic derrangements will precede contractile dysfunction, we 
evaluated changes in glucose metabolism (glucose uptake and MMRG) and oxidative 
metabolism (MVO2) along with cardiac perfusion (MBF), as an approach to uncover any 
pattern of early alterations that could provide clues about the onset of toxicity. However, 
we did not detect changes in those metabolic parameters, as evaluated with FDG and 11C-
acetate PET, suggesting that LV dysfunction can arise in the absence of overt metabolic 
damage early during sunitinib treatment. 
 
Other analyses revealed structural cardiac damage such as mild histopathological 
alterations and collagen deposition after 4 weeks of treatment with sunitinib. In addition, 
electron microscopy showed ultrastructural mitocondrial injury and deposition of 
cytoplasmic lipid droplets in the cardiomyocytes. The degree and frequency of these 
alterations suggest that they are just emerging at week 4 but this interpretation needs to be 
confirmed experimentally by similar analyses at early time points of the treatment. In 
addition, we found evidences of myocardial inflammation and remodeling by gene 
expression analyses and immunofluorescence, which may be interpreted as a reflection of 
tissue injury.  
 
In summary, we have established a working model of sunitinib cardiac toxicity in mice; our 
study indicates that a 4-weeks treatment with sunitinib at 80mg/Kg/day in male C57BL/6 
mice is sufficient to induce early left ventricular dysfunction that eventually progresses to 
grade-2 heart failure. We also showed that the early LV dysfunction does not correlate with 
overt alterations in cardiac glucose and oxidative metabolism detectable by FDG- and 11C-
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acetate-PET. Gene expression analyses and intracellular lipid droplets accumulation, 
detected at the end of the study, point to some defect in long-chain fatty acids utilization by 
the myocardium but this possibility needs to be addressed experimentally in separate 
studies.  
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7. PERSPECTIVES 
 
The results presented here suggest that the 4-weeks treatment with sunitinib with the dose 
and schedule used did not trigger an overt metabolic damage neither a switch in substrate 
utilization detectable by 11C-acetate and FDG-PET. Interestingly, we have been unable to 
find any published work reporting the occurrence of such a metabolic switch during 
sunitinib treatment. Since this is the first time that we use this model of sunitinib 
cardiotoxicity, we consider that a full characterization of the model is a critical step for 
future studies. We recommend several variations that can be applied alone or in 
combination, to explore the occurrence of metabolic, structural and functional toxicity and 
better characterize the nature of sunitinib-induced damage. 
 
Based on the assumption that the histopathological and mitochondrial damage, and the 
changes in gene expression observed after four weeks of treatment are in the early stages, 
we recommend to extend the time of treatment as performed here for 1-2 more weeks and 
evaluate the same parameters. This may provide a clear indication regarding the timeline of 
appearance of metabolic derangements in this model. Also, an administration schedule of 7 
days/week (which eliminates the 2 days-off/week used in this study) can be assayed as it is 
known that early stage damage by sunitinib may be reversible (Mellor et al., 2011; 
Monsuez et al., 2010). 
 
An important aspect of the full characterization of the model will be the incorporation of 
in-depth gene expression and/or functional metabolic studies, as well as histopathological 
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assessments starting from the first week of treatment. These could be done either 
independently or in parallel with PET measurement of cardiac function and metabolic flux 
but in any case, they are decisive to generate independent data on sunitinib toxicity and to 
facilitate a better interpretation of any metabolic phenotype uncovered by PET. One key 
issue not addressed in our study is the monitoring of tyroid hormones (T3 and T4) levels. As 
discussed above, hypothyroidism is a known side effect of sunitinib and could be an 
important contributor to cardiac dysfunction by mechanisms not directly related to energy 
generation. Thyroid function can be evaluated by blood biochemistry, it can provide 
important information regarding contractile dysfunction that can ultimately complement 
PET results. 
 
Cardiac PET using 11C-acetate evaluates oxidative metabolism. However it is unable to 
provide direct data on fatty acids β-oxidation. This is a particularly interesting question 
given our results showing changes of expression in critical genes involved on fatty acids 
metabolism, and the accumulation of intracytoplasmic lipid droplets, which suggest the 
existence of alterations in the metabolism of long-chain fatty acids. To generate such data, 
a radiotracer such as 11C-palmitate could be used; the kinetics of this long-chain fatty acid 
analog is identical to native, unlabeled palmitate thus it can provide direct information on 
β-oxidation (Heather et al., 2006; Peterson and Gropler, 2010; Tuunanen et al., 2008). 
These studies can be done in combination with the use of perhexiline, a potent inhibitor of 
carnitine palmitoyltransferase-1 (CPT-1) and carnitine palmitoyltransferase-2 (CPT-2) 
(Kennedy et al., 2000) as a positive control. Perhexiline shifts the metabolism from the use 
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of free fatty acids to glucose utilization (Barba et al., 2009; Lee et al., 2005) thus it can 
provide a clear signature of defective fatty acids metabolism.  
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